Dosing Guide

Regulatory Notice (September 2026 — FDA Enforcement): On August 24, 2026, the FDA issued warning letters to five online peptide vendors — NuScience Peptides LLC, Royal Peptides LLC, Peak Performance Peptides, Peptide Partners LLC, and TXP Innovations LLC dba Tex Peptides — citing Tesamorelin as an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act. Note: FDA-approved Egrifta SV (tesamorelin) is approved for HIV-related lipodystrophy, but research-use tesamorelin sold by these vendors outside that approved indication is unapproved. The letters were published on FDA.gov on September 1, 2026, and give recipients 15 days to respond. Sources: FDA warning letters (fda.gov, August 24, 2026): Peak Performance Peptides #735127; pharmaphorum (September 2, 2026).

Regulatory Notice (September 2026 — FDA Enforcement): On August 24, 2026, the FDA issued warning letters to five online peptide vendors — NuScience Peptides LLC, Royal Peptides LLC, Peak Performance Peptides, Peptide Partners LLC, and TXP Innovations LLC dba Tex Peptides — citing Tesamorelin as an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act. Note: FDA-approved Egrifta SV (tesamorelin) is approved for HIV-related lipodystrophy, but research-use tesamorelin sold by these vendors outside that approved indication is unapproved. The letters were published on FDA.gov on September 1, 2026, and give recipients 15 days to respond. Sources: FDA warning letters (fda.gov, August 24, 2026): Peak Performance Peptides #735127; pharmaphorum (September 2, 2026).

Regulatory Notice (September 2026 — FDA Enforcement): On August 24, 2026, the FDA issued warning letters to five online peptide vendors — NuScience Peptides LLC, Royal Peptides LLC, Peak Performance Peptides, Peptide Partners LLC, and TXP Innovations LLC dba Tex Peptides — citing Tesamorelin as an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act. Note: FDA-approved Egrifta SV (tesamorelin) is approved for HIV-related lipodystrophy, but research-use tesamorelin sold by these vendors outside that approved indication is unapproved. The letters were published on FDA.gov on September 1, 2026, and give recipients 15 days to respond. Sources: FDA warning letters (fda.gov, August 24, 2026): Peak Performance Peptides #735127; pharmaphorum (September 2, 2026).

Regulatory Notice (September 2026 — FDA Enforcement): On August 24, 2026, the FDA issued warning letters to five online peptide vendors — NuScience Peptides LLC, Royal Peptides LLC, Peak Performance Peptides, Peptide Partners LLC, and TXP Innovations LLC dba Tex Peptides — citing Tesamorelin as an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act. Note: FDA-approved Egrifta SV (tesamorelin) is approved for HIV-related lipodystrophy, but research-use tesamorelin sold by these vendors outside that approved indication is unapproved. The letters were published on FDA.gov on September 1, 2026, and give recipients 15 days to respond. Sources: FDA warning letters (fda.gov, August 24, 2026): Peak Performance Peptides #735127; pharmaphorum (September 2, 2026).

Regulatory Notice (May 2026): The FDA proposed on April 30, 2026 to remove Semaglutide and Tirzepatide from the 503B compounding bulks list. The national shortage designation has been resolved. Compounded versions of these compounds may face legal restrictions. Verify current FDA compounding status in your region before sourcing.

Regulatory Notice (August 2026): On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulk drug substances list — finding no clinical need for compounding. The public comment period, initially set to close June 29, 2026, was extended and formally closed on July 30, 2026 (3,901 public comments received). The FDA is now reviewing submitted comments before issuing a final rule (expected within 6–12 months). If finalized, 503B outsourcing facilities will be permanently barred from compounding these agents from bulk API, even if future drug shortages arise. Patient-specific 503A compounding remains a separate pathway. Sources: FDA.gov (April 30, 2026); Federal Register 2026-08552; Medical Daily (July 30, 2026); Science-Based Medicine. FDA Enforcement Action — Misleading Compounded GLP-1 Marketing (March 3, 2026): On March 3, 2026, the FDA issued 30 warning letters to telehealth companies for making false or misleading marketing claims about compounded GLP-1 receptor agonist products, including claims implying equivalence to FDA-approved brand-name medications (Ozempic, Wegovy, Mounjaro, Zepbound) and branding that obscured the identity of the actual compounder. This is a distinct enforcement action — separate from the 503B exclusion proposal (April 30, 2026) — and targets promotional violations rather than compounding authorization. Researchers and clinicians following this space should be aware that FDA is actively enforcing truthful labeling rules in the compounded GLP-1 market. Source: FDA press announcement (fda.gov, March 3, 2026); Reuters (March 3, 2026). Fifth Circuit Court of Appeals — GLP-1 Compounding Ruling (August 27, 2026): On August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit affirmed two lower-court judgments upholding the FDA's removal of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) from the national drug shortage list. Because federal law (21 U.S.C. § 353a/353b) only permits compounding copies of an approved drug while it remains in shortage, this ruling removes the shortage-based legal basis for bulk compounding of these agents. 503A patient-specific compounding for individual patients with documented medical needs remains a separate, narrower pathway. 503B outsourcing facility bulk production of essentially-equivalent copies is no longer supported by a shortage justification. The ruling does not affect the separate FDA rulemaking (503B exclusion proposal, April 30, 2026) which is still under agency review. Sources: teleranked.com (August 27, 2026); peptidesbeat.com (August 27, 2026); courthousenews.com. FDA Import Alert 66-80 — GLP-1 API Detention (August 21, 2026): On August 21, 2026, the FDA published a major revision to Import Alert 66-80, authorising Detention Without Physical Examination (DWPE) of foreign-sourced GLP-1 receptor agonist bulk drug substances — including semaglutide, tirzepatide, liraglutide, exenatide, dulaglutide, and related peptide APIs — at U.S. ports of entry. The alert accompanies the FDA's "green list" program: manufacturers that have passed FDA inspection and cGMP review can apply to be exempted from automatic detention. Facilities that have not responded to FDA inspection requests or have been found non-compliant remain subject to DWPE. Practically, this means bulk GLP-1 API imported from foreign sources without green-list status can be detained and refused entry without individual inspection. This is a supply-chain enforcement tool targeting the import of raw GLP-1 peptide APIs used in compounding; it does not change whether compounding is otherwise permitted. The alert operates in parallel with the ongoing 503B exclusion rulemaking (comment period closed July 30, 2026, final rule pending) and the Fifth Circuit ruling (August 27, 2026) upholding removal of these agents from shortage status. Source: FDA Import Alert 66-80, accessdata.fda.gov (August 21, 2026); FDA press announcement (fda.gov); Frier Levitt (frierlevitt.com); PeptideKnow.com. TGA Counterfeit Alert (September 14, 2026): A product sold in Australia as 'retatrutide' was confirmed by TGA laboratory testing to contain undeclared semaglutide at a high dose, not retatrutide. The patient who consumed it suffered a torn oesophagus requiring hospitalisation. This incident reinforces that illicit injectable products sold outside authorised channels may contain undisclosed active ingredients and pose serious safety risks. Sources: ABC News Australia (abc.net.au, September 14, 2026); The Guardian Australia (theguardian.com, September 14, 2026).

Regulatory Notice (May 2026): The FDA proposed on April 30, 2026 to remove Semaglutide and Tirzepatide from the 503B compounding bulks list. The national shortage designation has been resolved. Compounded versions of these compounds may face legal restrictions. Verify current FDA compounding status in your region before sourcing.

Regulatory Notice (August 2026): On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulk drug substances list — finding no clinical need for compounding. The public comment period, initially set to close June 29, 2026, was extended and formally closed on July 30, 2026 (3,901 public comments received). The FDA is now reviewing submitted comments before issuing a final rule (expected within 6–12 months). If finalized, 503B outsourcing facilities will be permanently barred from compounding these agents from bulk API, even if future drug shortages arise. Patient-specific 503A compounding remains a separate pathway. Sources: FDA.gov (April 30, 2026); Federal Register 2026-08552; Medical Daily (July 30, 2026); Science-Based Medicine. FDA Enforcement Action — Misleading Compounded GLP-1 Marketing (March 3, 2026): On March 3, 2026, the FDA issued 30 warning letters to telehealth companies for making false or misleading marketing claims about compounded GLP-1 receptor agonist products, including claims implying equivalence to FDA-approved brand-name medications (Ozempic, Wegovy, Mounjaro, Zepbound) and branding that obscured the identity of the actual compounder. This is a distinct enforcement action — separate from the 503B exclusion proposal (April 30, 2026) — and targets promotional violations rather than compounding authorization. Researchers and clinicians following this space should be aware that FDA is actively enforcing truthful labeling rules in the compounded GLP-1 market. Source: FDA press announcement (fda.gov, March 3, 2026); Reuters (March 3, 2026). Fifth Circuit Court of Appeals — GLP-1 Compounding Ruling (August 27, 2026): On August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit affirmed two lower-court judgments upholding the FDA's removal of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) from the national drug shortage list. Because federal law (21 U.S.C. § 353a/353b) only permits compounding copies of an approved drug while it remains in shortage, this ruling removes the shortage-based legal basis for bulk compounding of these agents. 503A patient-specific compounding for individual patients with documented medical needs remains a separate, narrower pathway. 503B outsourcing facility bulk production of essentially-equivalent copies is no longer supported by a shortage justification. The ruling does not affect the separate FDA rulemaking (503B exclusion proposal, April 30, 2026) which is still under agency review. Sources: teleranked.com (August 27, 2026); peptidesbeat.com (August 27, 2026); courthousenews.com. FDA Import Alert 66-80 — GLP-1 API Detention (August 21, 2026): On August 21, 2026, the FDA published a major revision to Import Alert 66-80, authorising Detention Without Physical Examination (DWPE) of foreign-sourced GLP-1 receptor agonist bulk drug substances — including semaglutide, tirzepatide, liraglutide, exenatide, dulaglutide, and related peptide APIs — at U.S. ports of entry. The alert accompanies the FDA's "green list" program: manufacturers that have passed FDA inspection and cGMP review can apply to be exempted from automatic detention. Facilities that have not responded to FDA inspection requests or have been found non-compliant remain subject to DWPE. Practically, this means bulk GLP-1 API imported from foreign sources without green-list status can be detained and refused entry without individual inspection. This is a supply-chain enforcement tool targeting the import of raw GLP-1 peptide APIs used in compounding; it does not change whether compounding is otherwise permitted. The alert operates in parallel with the ongoing 503B exclusion rulemaking (comment period closed July 30, 2026, final rule pending) and the Fifth Circuit ruling (August 27, 2026) upholding removal of these agents from shortage status. Source: FDA Import Alert 66-80, accessdata.fda.gov (August 21, 2026); FDA press announcement (fda.gov); Frier Levitt (frierlevitt.com); PeptideKnow.com. TGA Counterfeit Alert (September 14, 2026): A product sold in Australia as 'retatrutide' was confirmed by TGA laboratory testing to contain undeclared semaglutide at a high dose, not retatrutide. The patient who consumed it suffered a torn oesophagus requiring hospitalisation. This incident reinforces that illicit injectable products sold outside authorised channels may contain undisclosed active ingredients and pose serious safety risks. Sources: ABC News Australia (abc.net.au, September 14, 2026); The Guardian Australia (theguardian.com, September 14, 2026).

Regulatory Notice (May 2026): The FDA proposed on April 30, 2026 to remove Semaglutide and Tirzepatide from the 503B compounding bulks list. The national shortage designation has been resolved. Compounded versions of these compounds may face legal restrictions. Verify current FDA compounding status in your region before sourcing.

Regulatory Notice (August 2026): On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulk drug substances list — finding no clinical need for compounding. The public comment period, initially set to close June 29, 2026, was extended and formally closed on July 30, 2026 (3,901 public comments received). The FDA is now reviewing submitted comments before issuing a final rule (expected within 6–12 months). If finalized, 503B outsourcing facilities will be permanently barred from compounding these agents from bulk API, even if future drug shortages arise. Patient-specific 503A compounding remains a separate pathway. Sources: FDA.gov (April 30, 2026); Federal Register 2026-08552; Medical Daily (July 30, 2026); Science-Based Medicine. FDA Enforcement Action — Misleading Compounded GLP-1 Marketing (March 3, 2026): On March 3, 2026, the FDA issued 30 warning letters to telehealth companies for making false or misleading marketing claims about compounded GLP-1 receptor agonist products, including claims implying equivalence to FDA-approved brand-name medications (Ozempic, Wegovy, Mounjaro, Zepbound) and branding that obscured the identity of the actual compounder. This is a distinct enforcement action — separate from the 503B exclusion proposal (April 30, 2026) — and targets promotional violations rather than compounding authorization. Researchers and clinicians following this space should be aware that FDA is actively enforcing truthful labeling rules in the compounded GLP-1 market. Source: FDA press announcement (fda.gov, March 3, 2026); Reuters (March 3, 2026). Fifth Circuit Court of Appeals — GLP-1 Compounding Ruling (August 27, 2026): On August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit affirmed two lower-court judgments upholding the FDA's removal of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) from the national drug shortage list. Because federal law (21 U.S.C. § 353a/353b) only permits compounding copies of an approved drug while it remains in shortage, this ruling removes the shortage-based legal basis for bulk compounding of these agents. 503A patient-specific compounding for individual patients with documented medical needs remains a separate, narrower pathway. 503B outsourcing facility bulk production of essentially-equivalent copies is no longer supported by a shortage justification. The ruling does not affect the separate FDA rulemaking (503B exclusion proposal, April 30, 2026) which is still under agency review. Sources: teleranked.com (August 27, 2026); peptidesbeat.com (August 27, 2026); courthousenews.com. FDA Import Alert 66-80 — GLP-1 API Detention (August 21, 2026): On August 21, 2026, the FDA published a major revision to Import Alert 66-80, authorising Detention Without Physical Examination (DWPE) of foreign-sourced GLP-1 receptor agonist bulk drug substances — including semaglutide, tirzepatide, liraglutide, exenatide, dulaglutide, and related peptide APIs — at U.S. ports of entry. The alert accompanies the FDA's "green list" program: manufacturers that have passed FDA inspection and cGMP review can apply to be exempted from automatic detention. Facilities that have not responded to FDA inspection requests or have been found non-compliant remain subject to DWPE. Practically, this means bulk GLP-1 API imported from foreign sources without green-list status can be detained and refused entry without individual inspection. This is a supply-chain enforcement tool targeting the import of raw GLP-1 peptide APIs used in compounding; it does not change whether compounding is otherwise permitted. The alert operates in parallel with the ongoing 503B exclusion rulemaking (comment period closed July 30, 2026, final rule pending) and the Fifth Circuit ruling (August 27, 2026) upholding removal of these agents from shortage status. Source: FDA Import Alert 66-80, accessdata.fda.gov (August 21, 2026); FDA press announcement (fda.gov); Frier Levitt (frierlevitt.com); PeptideKnow.com. TGA Counterfeit Alert (September 14, 2026): A product sold in Australia as 'retatrutide' was confirmed by TGA laboratory testing to contain undeclared semaglutide at a high dose, not retatrutide. The patient who consumed it suffered a torn oesophagus requiring hospitalisation. This incident reinforces that illicit injectable products sold outside authorised channels may contain undisclosed active ingredients and pose serious safety risks. Sources: ABC News Australia (abc.net.au, September 14, 2026); The Guardian Australia (theguardian.com, September 14, 2026).

Regulatory Notice (May 2026): The FDA proposed on April 30, 2026 to remove Semaglutide and Tirzepatide from the 503B compounding bulks list. The national shortage designation has been resolved. Compounded versions of these compounds may face legal restrictions. Verify current FDA compounding status in your region before sourcing.

Regulatory Notice (August 2026): On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulk drug substances list — finding no clinical need for compounding. The public comment period, initially set to close June 29, 2026, was extended and formally closed on July 30, 2026 (3,901 public comments received). The FDA is now reviewing submitted comments before issuing a final rule (expected within 6–12 months). If finalized, 503B outsourcing facilities will be permanently barred from compounding these agents from bulk API, even if future drug shortages arise. Patient-specific 503A compounding remains a separate pathway. Sources: FDA.gov (April 30, 2026); Federal Register 2026-08552; Medical Daily (July 30, 2026); Science-Based Medicine. FDA Enforcement Action — Misleading Compounded GLP-1 Marketing (March 3, 2026): On March 3, 2026, the FDA issued 30 warning letters to telehealth companies for making false or misleading marketing claims about compounded GLP-1 receptor agonist products, including claims implying equivalence to FDA-approved brand-name medications (Ozempic, Wegovy, Mounjaro, Zepbound) and branding that obscured the identity of the actual compounder. This is a distinct enforcement action — separate from the 503B exclusion proposal (April 30, 2026) — and targets promotional violations rather than compounding authorization. Researchers and clinicians following this space should be aware that FDA is actively enforcing truthful labeling rules in the compounded GLP-1 market. Source: FDA press announcement (fda.gov, March 3, 2026); Reuters (March 3, 2026). Fifth Circuit Court of Appeals — GLP-1 Compounding Ruling (August 27, 2026): On August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit affirmed two lower-court judgments upholding the FDA's removal of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) from the national drug shortage list. Because federal law (21 U.S.C. § 353a/353b) only permits compounding copies of an approved drug while it remains in shortage, this ruling removes the shortage-based legal basis for bulk compounding of these agents. 503A patient-specific compounding for individual patients with documented medical needs remains a separate, narrower pathway. 503B outsourcing facility bulk production of essentially-equivalent copies is no longer supported by a shortage justification. The ruling does not affect the separate FDA rulemaking (503B exclusion proposal, April 30, 2026) which is still under agency review. Sources: teleranked.com (August 27, 2026); peptidesbeat.com (August 27, 2026); courthousenews.com. FDA Import Alert 66-80 — GLP-1 API Detention (August 21, 2026): On August 21, 2026, the FDA published a major revision to Import Alert 66-80, authorising Detention Without Physical Examination (DWPE) of foreign-sourced GLP-1 receptor agonist bulk drug substances — including semaglutide, tirzepatide, liraglutide, exenatide, dulaglutide, and related peptide APIs — at U.S. ports of entry. The alert accompanies the FDA's "green list" program: manufacturers that have passed FDA inspection and cGMP review can apply to be exempted from automatic detention. Facilities that have not responded to FDA inspection requests or have been found non-compliant remain subject to DWPE. Practically, this means bulk GLP-1 API imported from foreign sources without green-list status can be detained and refused entry without individual inspection. This is a supply-chain enforcement tool targeting the import of raw GLP-1 peptide APIs used in compounding; it does not change whether compounding is otherwise permitted. The alert operates in parallel with the ongoing 503B exclusion rulemaking (comment period closed July 30, 2026, final rule pending) and the Fifth Circuit ruling (August 27, 2026) upholding removal of these agents from shortage status. Source: FDA Import Alert 66-80, accessdata.fda.gov (August 21, 2026); FDA press announcement (fda.gov); Frier Levitt (frierlevitt.com); PeptideKnow.com. TGA Counterfeit Alert (September 14, 2026): A product sold in Australia as 'retatrutide' was confirmed by TGA laboratory testing to contain undeclared semaglutide at a high dose, not retatrutide. The patient who consumed it suffered a torn oesophagus requiring hospitalisation. This incident reinforces that illicit injectable products sold outside authorised channels may contain undisclosed active ingredients and pose serious safety risks. Sources: ABC News Australia (abc.net.au, September 14, 2026); The Guardian Australia (theguardian.com, September 14, 2026).

Regulatory Notice (May 2026): The FDA proposed on April 30, 2026 to remove Semaglutide and Tirzepatide from the 503B compounding bulks list. The national shortage designation has been resolved. Compounded versions of these compounds may face legal restrictions. Verify current FDA compounding status in your region before sourcing.

Regulatory Notice (August 2026): On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulk drug substances list — finding no clinical need for compounding. The public comment period, initially set to close June 29, 2026, was extended and formally closed on July 30, 2026 (3,901 public comments received). The FDA is now reviewing submitted comments before issuing a final rule (expected within 6–12 months). If finalized, 503B outsourcing facilities will be permanently barred from compounding these agents from bulk API, even if future drug shortages arise. Patient-specific 503A compounding remains a separate pathway. Sources: FDA.gov (April 30, 2026); Federal Register 2026-08552; Medical Daily (July 30, 2026); Science-Based Medicine. FDA Label Expansion — Cardiovascular Risk Reduction (August 28, 2026): The FDA approved a new indication for tirzepatide (Mounjaro; Eli Lilly) to reduce the risk of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors. This approval was based on the SURPASS-CVOT cardiovascular outcomes trial. This is a label expansion for an already-approved prescription drug (Mounjaro). Compounded tirzepatide remains outside this approval — the expanded label applies solely to the brand-name pharmaceutical product. Source: Eli Lilly investor press release (investor.lilly.com, August 28, 2026); Cardiovascular Business (August 28, 2026); Reuters (August 28, 2026). FDA Enforcement Action — Misleading Compounded GLP-1 Marketing (March 3, 2026): On March 3, 2026, the FDA issued 30 warning letters to telehealth companies for making false or misleading marketing claims about compounded GLP-1 receptor agonist products, including claims implying equivalence to FDA-approved brand-name medications (Ozempic, Wegovy, Mounjaro, Zepbound) and branding that obscured the identity of the actual compounder. This is a distinct enforcement action — separate from the 503B exclusion proposal (April 30, 2026) — and targets promotional violations rather than compounding authorization. Researchers and clinicians following this space should be aware that FDA is actively enforcing truthful labeling rules in the compounded GLP-1 market. Source: FDA press announcement (fda.gov, March 3, 2026); Reuters (March 3, 2026). Fifth Circuit Court of Appeals — GLP-1 Compounding Ruling (August 27, 2026): On August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit affirmed two lower-court judgments upholding the FDA's removal of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) from the national drug shortage list. Because federal law (21 U.S.C. § 353a/353b) only permits compounding copies of an approved drug while it remains in shortage, this ruling removes the shortage-based legal basis for bulk compounding of these agents. 503A patient-specific compounding for individual patients with documented medical needs remains a separate, narrower pathway. 503B outsourcing facility bulk production of essentially-equivalent copies is no longer supported by a shortage justification. The ruling does not affect the separate FDA rulemaking (503B exclusion proposal, April 30, 2026) which is still under agency review. Sources: teleranked.com (August 27, 2026); peptidesbeat.com (August 27, 2026); courthousenews.com. FDA Import Alert 66-80 — GLP-1 API Detention (August 21, 2026): On August 21, 2026, the FDA published a major revision to Import Alert 66-80, authorising Detention Without Physical Examination (DWPE) of foreign-sourced GLP-1 receptor agonist bulk drug substances — including semaglutide, tirzepatide, liraglutide, exenatide, dulaglutide, and related peptide APIs — at U.S. ports of entry. The alert accompanies the FDA's "green list" program: manufacturers that have passed FDA inspection and cGMP review can apply to be exempted from automatic detention. Facilities that have not responded to FDA inspection requests or have been found non-compliant remain subject to DWPE. Practically, this means bulk GLP-1 API imported from foreign sources without green-list status can be detained and refused entry without individual inspection. This is a supply-chain enforcement tool targeting the import of raw GLP-1 peptide APIs used in compounding; it does not change whether compounding is otherwise permitted. The alert operates in parallel with the ongoing 503B exclusion rulemaking (comment period closed July 30, 2026, final rule pending) and the Fifth Circuit ruling (August 27, 2026) upholding removal of these agents from shortage status. Source: FDA Import Alert 66-80, accessdata.fda.gov (August 21, 2026); FDA press announcement (fda.gov); Frier Levitt (frierlevitt.com); PeptideKnow.com.

Regulatory Notice (May 2026): The FDA proposed on April 30, 2026 to remove Semaglutide and Tirzepatide from the 503B compounding bulks list. The national shortage designation has been resolved. Compounded versions of these compounds may face legal restrictions. Verify current FDA compounding status in your region before sourcing.

Regulatory Notice (August 2026): On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulk drug substances list — finding no clinical need for compounding. The public comment period, initially set to close June 29, 2026, was extended and formally closed on July 30, 2026 (3,901 public comments received). The FDA is now reviewing submitted comments before issuing a final rule (expected within 6–12 months). If finalized, 503B outsourcing facilities will be permanently barred from compounding these agents from bulk API, even if future drug shortages arise. Patient-specific 503A compounding remains a separate pathway. Sources: FDA.gov (April 30, 2026); Federal Register 2026-08552; Medical Daily (July 30, 2026); Science-Based Medicine. FDA Label Expansion — Cardiovascular Risk Reduction (August 28, 2026): The FDA approved a new indication for tirzepatide (Mounjaro; Eli Lilly) to reduce the risk of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors. This approval was based on the SURPASS-CVOT cardiovascular outcomes trial. This is a label expansion for an already-approved prescription drug (Mounjaro). Compounded tirzepatide remains outside this approval — the expanded label applies solely to the brand-name pharmaceutical product. Source: Eli Lilly investor press release (investor.lilly.com, August 28, 2026); Cardiovascular Business (August 28, 2026); Reuters (August 28, 2026). FDA Enforcement Action — Misleading Compounded GLP-1 Marketing (March 3, 2026): On March 3, 2026, the FDA issued 30 warning letters to telehealth companies for making false or misleading marketing claims about compounded GLP-1 receptor agonist products, including claims implying equivalence to FDA-approved brand-name medications (Ozempic, Wegovy, Mounjaro, Zepbound) and branding that obscured the identity of the actual compounder. This is a distinct enforcement action — separate from the 503B exclusion proposal (April 30, 2026) — and targets promotional violations rather than compounding authorization. Researchers and clinicians following this space should be aware that FDA is actively enforcing truthful labeling rules in the compounded GLP-1 market. Source: FDA press announcement (fda.gov, March 3, 2026); Reuters (March 3, 2026). Fifth Circuit Court of Appeals — GLP-1 Compounding Ruling (August 27, 2026): On August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit affirmed two lower-court judgments upholding the FDA's removal of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) from the national drug shortage list. Because federal law (21 U.S.C. § 353a/353b) only permits compounding copies of an approved drug while it remains in shortage, this ruling removes the shortage-based legal basis for bulk compounding of these agents. 503A patient-specific compounding for individual patients with documented medical needs remains a separate, narrower pathway. 503B outsourcing facility bulk production of essentially-equivalent copies is no longer supported by a shortage justification. The ruling does not affect the separate FDA rulemaking (503B exclusion proposal, April 30, 2026) which is still under agency review. Sources: teleranked.com (August 27, 2026); peptidesbeat.com (August 27, 2026); courthousenews.com. FDA Import Alert 66-80 — GLP-1 API Detention (August 21, 2026): On August 21, 2026, the FDA published a major revision to Import Alert 66-80, authorising Detention Without Physical Examination (DWPE) of foreign-sourced GLP-1 receptor agonist bulk drug substances — including semaglutide, tirzepatide, liraglutide, exenatide, dulaglutide, and related peptide APIs — at U.S. ports of entry. The alert accompanies the FDA's "green list" program: manufacturers that have passed FDA inspection and cGMP review can apply to be exempted from automatic detention. Facilities that have not responded to FDA inspection requests or have been found non-compliant remain subject to DWPE. Practically, this means bulk GLP-1 API imported from foreign sources without green-list status can be detained and refused entry without individual inspection. This is a supply-chain enforcement tool targeting the import of raw GLP-1 peptide APIs used in compounding; it does not change whether compounding is otherwise permitted. The alert operates in parallel with the ongoing 503B exclusion rulemaking (comment period closed July 30, 2026, final rule pending) and the Fifth Circuit ruling (August 27, 2026) upholding removal of these agents from shortage status. Source: FDA Import Alert 66-80, accessdata.fda.gov (August 21, 2026); FDA press announcement (fda.gov); Frier Levitt (frierlevitt.com); PeptideKnow.com.

Regulatory Notice (May 2026): The FDA proposed on April 30, 2026 to remove Semaglutide and Tirzepatide from the 503B compounding bulks list. The national shortage designation has been resolved. Compounded versions of these compounds may face legal restrictions. Verify current FDA compounding status in your region before sourcing.

Regulatory Notice (August 2026): On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulk drug substances list — finding no clinical need for compounding. The public comment period, initially set to close June 29, 2026, was extended and formally closed on July 30, 2026 (3,901 public comments received). The FDA is now reviewing submitted comments before issuing a final rule (expected within 6–12 months). If finalized, 503B outsourcing facilities will be permanently barred from compounding these agents from bulk API, even if future drug shortages arise. Patient-specific 503A compounding remains a separate pathway. Sources: FDA.gov (April 30, 2026); Federal Register 2026-08552; Medical Daily (July 30, 2026); Science-Based Medicine. FDA Label Expansion — Cardiovascular Risk Reduction (August 28, 2026): The FDA approved a new indication for tirzepatide (Mounjaro; Eli Lilly) to reduce the risk of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors. This approval was based on the SURPASS-CVOT cardiovascular outcomes trial. This is a label expansion for an already-approved prescription drug (Mounjaro). Compounded tirzepatide remains outside this approval — the expanded label applies solely to the brand-name pharmaceutical product. Source: Eli Lilly investor press release (investor.lilly.com, August 28, 2026); Cardiovascular Business (August 28, 2026); Reuters (August 28, 2026). FDA Enforcement Action — Misleading Compounded GLP-1 Marketing (March 3, 2026): On March 3, 2026, the FDA issued 30 warning letters to telehealth companies for making false or misleading marketing claims about compounded GLP-1 receptor agonist products, including claims implying equivalence to FDA-approved brand-name medications (Ozempic, Wegovy, Mounjaro, Zepbound) and branding that obscured the identity of the actual compounder. This is a distinct enforcement action — separate from the 503B exclusion proposal (April 30, 2026) — and targets promotional violations rather than compounding authorization. Researchers and clinicians following this space should be aware that FDA is actively enforcing truthful labeling rules in the compounded GLP-1 market. Source: FDA press announcement (fda.gov, March 3, 2026); Reuters (March 3, 2026). Fifth Circuit Court of Appeals — GLP-1 Compounding Ruling (August 27, 2026): On August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit affirmed two lower-court judgments upholding the FDA's removal of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) from the national drug shortage list. Because federal law (21 U.S.C. § 353a/353b) only permits compounding copies of an approved drug while it remains in shortage, this ruling removes the shortage-based legal basis for bulk compounding of these agents. 503A patient-specific compounding for individual patients with documented medical needs remains a separate, narrower pathway. 503B outsourcing facility bulk production of essentially-equivalent copies is no longer supported by a shortage justification. The ruling does not affect the separate FDA rulemaking (503B exclusion proposal, April 30, 2026) which is still under agency review. Sources: teleranked.com (August 27, 2026); peptidesbeat.com (August 27, 2026); courthousenews.com. FDA Import Alert 66-80 — GLP-1 API Detention (August 21, 2026): On August 21, 2026, the FDA published a major revision to Import Alert 66-80, authorising Detention Without Physical Examination (DWPE) of foreign-sourced GLP-1 receptor agonist bulk drug substances — including semaglutide, tirzepatide, liraglutide, exenatide, dulaglutide, and related peptide APIs — at U.S. ports of entry. The alert accompanies the FDA's "green list" program: manufacturers that have passed FDA inspection and cGMP review can apply to be exempted from automatic detention. Facilities that have not responded to FDA inspection requests or have been found non-compliant remain subject to DWPE. Practically, this means bulk GLP-1 API imported from foreign sources without green-list status can be detained and refused entry without individual inspection. This is a supply-chain enforcement tool targeting the import of raw GLP-1 peptide APIs used in compounding; it does not change whether compounding is otherwise permitted. The alert operates in parallel with the ongoing 503B exclusion rulemaking (comment period closed July 30, 2026, final rule pending) and the Fifth Circuit ruling (August 27, 2026) upholding removal of these agents from shortage status. Source: FDA Import Alert 66-80, accessdata.fda.gov (August 21, 2026); FDA press announcement (fda.gov); Frier Levitt (frierlevitt.com); PeptideKnow.com.

Regulatory Notice (May 2026): The FDA proposed on April 30, 2026 to remove Semaglutide and Tirzepatide from the 503B compounding bulks list. The national shortage designation has been resolved. Compounded versions of these compounds may face legal restrictions. Verify current FDA compounding status in your region before sourcing.

Regulatory Notice (August 2026): On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulk drug substances list — finding no clinical need for compounding. The public comment period, initially set to close June 29, 2026, was extended and formally closed on July 30, 2026 (3,901 public comments received). The FDA is now reviewing submitted comments before issuing a final rule (expected within 6–12 months). If finalized, 503B outsourcing facilities will be permanently barred from compounding these agents from bulk API, even if future drug shortages arise. Patient-specific 503A compounding remains a separate pathway. Sources: FDA.gov (April 30, 2026); Federal Register 2026-08552; Medical Daily (July 30, 2026); Science-Based Medicine. FDA Label Expansion — Cardiovascular Risk Reduction (August 28, 2026): The FDA approved a new indication for tirzepatide (Mounjaro; Eli Lilly) to reduce the risk of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors. This approval was based on the SURPASS-CVOT cardiovascular outcomes trial. This is a label expansion for an already-approved prescription drug (Mounjaro). Compounded tirzepatide remains outside this approval — the expanded label applies solely to the brand-name pharmaceutical product. Source: Eli Lilly investor press release (investor.lilly.com, August 28, 2026); Cardiovascular Business (August 28, 2026); Reuters (August 28, 2026). FDA Enforcement Action — Misleading Compounded GLP-1 Marketing (March 3, 2026): On March 3, 2026, the FDA issued 30 warning letters to telehealth companies for making false or misleading marketing claims about compounded GLP-1 receptor agonist products, including claims implying equivalence to FDA-approved brand-name medications (Ozempic, Wegovy, Mounjaro, Zepbound) and branding that obscured the identity of the actual compounder. This is a distinct enforcement action — separate from the 503B exclusion proposal (April 30, 2026) — and targets promotional violations rather than compounding authorization. Researchers and clinicians following this space should be aware that FDA is actively enforcing truthful labeling rules in the compounded GLP-1 market. Source: FDA press announcement (fda.gov, March 3, 2026); Reuters (March 3, 2026). Fifth Circuit Court of Appeals — GLP-1 Compounding Ruling (August 27, 2026): On August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit affirmed two lower-court judgments upholding the FDA's removal of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) from the national drug shortage list. Because federal law (21 U.S.C. § 353a/353b) only permits compounding copies of an approved drug while it remains in shortage, this ruling removes the shortage-based legal basis for bulk compounding of these agents. 503A patient-specific compounding for individual patients with documented medical needs remains a separate, narrower pathway. 503B outsourcing facility bulk production of essentially-equivalent copies is no longer supported by a shortage justification. The ruling does not affect the separate FDA rulemaking (503B exclusion proposal, April 30, 2026) which is still under agency review. Sources: teleranked.com (August 27, 2026); peptidesbeat.com (August 27, 2026); courthousenews.com. FDA Import Alert 66-80 — GLP-1 API Detention (August 21, 2026): On August 21, 2026, the FDA published a major revision to Import Alert 66-80, authorising Detention Without Physical Examination (DWPE) of foreign-sourced GLP-1 receptor agonist bulk drug substances — including semaglutide, tirzepatide, liraglutide, exenatide, dulaglutide, and related peptide APIs — at U.S. ports of entry. The alert accompanies the FDA's "green list" program: manufacturers that have passed FDA inspection and cGMP review can apply to be exempted from automatic detention. Facilities that have not responded to FDA inspection requests or have been found non-compliant remain subject to DWPE. Practically, this means bulk GLP-1 API imported from foreign sources without green-list status can be detained and refused entry without individual inspection. This is a supply-chain enforcement tool targeting the import of raw GLP-1 peptide APIs used in compounding; it does not change whether compounding is otherwise permitted. The alert operates in parallel with the ongoing 503B exclusion rulemaking (comment period closed July 30, 2026, final rule pending) and the Fifth Circuit ruling (August 27, 2026) upholding removal of these agents from shortage status. Source: FDA Import Alert 66-80, accessdata.fda.gov (August 21, 2026); FDA press announcement (fda.gov); Frier Levitt (frierlevitt.com); PeptideKnow.com.

Regulatory Notice (July 2026): Retatrutide is not FDA approved. The TRIUMPH-1 Phase 3 trial (2,339 participants, 80 weeks) reported a mean body weight reduction of 28.3%, with reductions up to 30.3% in higher-BMI cohorts — announced May 21, 2026. Additional TRIUMPH-1 secondary endpoints announced June 6, 2026 at ADA Scientific Sessions: 60.6% reduction in Apnea-Hypopnea Index in patients with obstructive sleep apnea (source: Eli Lilly investor release, investor.lilly.com). Update (July 23, 2026): Eli Lilly announced positive results from TRIUMPH-2 (adults with obesity and type 2 diabetes; 22.6% mean weight loss at 80 weeks) and TRIUMPH-3 (adults with severe obesity and cardiovascular disease; up to 22.6% mean weight loss at 80 weeks), completing the Phase 3 programme. Lilly confirmed it plans to submit a Biologics License Application (BLA) to the FDA in Q1 2027. FDA approval is not anticipated before late 2027 at the earliest. Sources: Eli Lilly press release July 23, 2026 (investor.lilly.com); PharmExec July 25, 2026; Pharmaphorum July 22, 2026. Retatrutide cannot be legally compounded under 503A or 503B. Research compound only. Enforcement Action (August 12, 2026): Eli Lilly filed six civil lawsuits against U.S. entities selling black-market, unapproved versions of retatrutide — an investigational compound that has not received FDA approval. Lilly simultaneously referred hundreds of additional bad actors to regulators and law enforcement worldwide, and called on online platforms and payment companies to shut off access to illicit sellers. The actions underscore that retatrutide cannot be legally compounded, sold, or distributed outside of the authorised clinical trial framework. Source: Eli Lilly investor press release (investor.lilly.com, August 12, 2026); Reuters (August 12, 2026); Healio (August 14, 2026). ANSM Safety Alert — France (July 2, 2026): France's national medicines regulatory agency (ANSM) published a formal public safety alert titled 'Peptides vendus en ligne: ne les utilisez pas, ils peuvent être dangereux' (Peptides sold online: do not use them, they can be dangerous). The alert cites pharmacovigilance reports of serious adverse events — including hospitalizations — in individuals aged 15 to 35 following use of injectable peptides purchased online, including retatrutide, BPC-157, TB-500, GHK-Cu, NAD+, and growth hormone products. The ANSM states that these compounds are not authorized or evaluated for human use in France, warns that products sold informally (online, social media, peer networks) are not subject to quality or safety controls, and flags a potential cancer-progression risk from unregulated cell-growth stimulants. The ANSM strongly advises the French public not to acquire or use these compounds. This alert does not affect the research-use legal status of these compounds globally but confirms that EU-member regulators are actively monitoring and taking enforcement action on the supply side. Source: ANSM (ansm.sante.fr, July 2, 2026); VIDAL.fr (July 2, 2026); AFP/actualites-sante.com (July 3, 2026). Biologic Classification Dispute — Seventh Circuit (August 2026): A federal court vacated the FDA's classification of retatrutide as a "drug" in September 2025 and remanded the question to the agency. Eli Lilly appealed to the Seventh Circuit Court of Appeals in February 2026, asking that retatrutide be classified as a biological product outright. Oral arguments before the Seventh Circuit are scheduled for September 24, 2026. The distinction is legally significant: a biologic classification would entitle Lilly to 12 years of exclusivity under the Biologics Price Competition and Innovation Act — longer than the standard 5-year New Chemical Entity exclusivity available for small-molecule drugs — and would permanently foreclose any compounding access, as biologics cannot be placed on the 503A or 503B Bulks Lists. The FDA's remand analysis (now required regardless of the court outcome) will also establish a binding standard for what makes a peptide "analogous to a protein," which may affect the classification of other large peptide therapeutics in development. No court ruling has been issued as of August 21, 2026. Sources: thepeptidetoolkit.com (May 21, 2026); compoundprotocol.com (August 11, 2026); BioSpace (August 5, 2026). TGA Safety Alert — Australia (September 14, 2026): Australia's Therapeutic Goods Administration issued a public safety warning after a patient suffered a torn oesophagus requiring hospitalisation following use of a product sold as retatrutide. Laboratory analysis confirmed the vial contained no retatrutide — instead it held a high and undeclared dose of semaglutide, consistent with deliberate counterfeiting. The TGA warns that illicit peptide products sold online — including those labelled as retatrutide — may be mislabelled, contaminated, or contain entirely different active substances. Consumers who experienced severe vomiting or GI symptoms after using such products are advised to seek immediate medical attention. Retatrutide is not approved by the TGA or any regulatory authority. The incident underscores the serious injury risk from counterfeit and unapproved injectable peptides obtained outside authorised clinical trial channels. Sources: ABC News Australia (abc.net.au, September 14, 2026); The Guardian Australia (theguardian.com, September 14, 2026); pharmex.co (September 14, 2026).

Regulatory Notice (July 2026): Retatrutide is not FDA approved. The TRIUMPH-1 Phase 3 trial (2,339 participants, 80 weeks) reported a mean body weight reduction of 28.3%, with reductions up to 30.3% in higher-BMI cohorts — announced May 21, 2026. Additional TRIUMPH-1 secondary endpoints announced June 6, 2026 at ADA Scientific Sessions: 60.6% reduction in Apnea-Hypopnea Index in patients with obstructive sleep apnea (source: Eli Lilly investor release, investor.lilly.com). Update (July 23, 2026): Eli Lilly announced positive results from TRIUMPH-2 (adults with obesity and type 2 diabetes; 22.6% mean weight loss at 80 weeks) and TRIUMPH-3 (adults with severe obesity and cardiovascular disease; up to 22.6% mean weight loss at 80 weeks), completing the Phase 3 programme. Lilly confirmed it plans to submit a Biologics License Application (BLA) to the FDA in Q1 2027. FDA approval is not anticipated before late 2027 at the earliest. Sources: Eli Lilly press release July 23, 2026 (investor.lilly.com); PharmExec July 25, 2026; Pharmaphorum July 22, 2026. Retatrutide cannot be legally compounded under 503A or 503B. Research compound only. Enforcement Action (August 12, 2026): Eli Lilly filed six civil lawsuits against U.S. entities selling black-market, unapproved versions of retatrutide — an investigational compound that has not received FDA approval. Lilly simultaneously referred hundreds of additional bad actors to regulators and law enforcement worldwide, and called on online platforms and payment companies to shut off access to illicit sellers. The actions underscore that retatrutide cannot be legally compounded, sold, or distributed outside of the authorised clinical trial framework. Source: Eli Lilly investor press release (investor.lilly.com, August 12, 2026); Reuters (August 12, 2026); Healio (August 14, 2026). ANSM Safety Alert — France (July 2, 2026): France's national medicines regulatory agency (ANSM) published a formal public safety alert titled 'Peptides vendus en ligne: ne les utilisez pas, ils peuvent être dangereux' (Peptides sold online: do not use them, they can be dangerous). The alert cites pharmacovigilance reports of serious adverse events — including hospitalizations — in individuals aged 15 to 35 following use of injectable peptides purchased online, including retatrutide, BPC-157, TB-500, GHK-Cu, NAD+, and growth hormone products. The ANSM states that these compounds are not authorized or evaluated for human use in France, warns that products sold informally (online, social media, peer networks) are not subject to quality or safety controls, and flags a potential cancer-progression risk from unregulated cell-growth stimulants. The ANSM strongly advises the French public not to acquire or use these compounds. This alert does not affect the research-use legal status of these compounds globally but confirms that EU-member regulators are actively monitoring and taking enforcement action on the supply side. Source: ANSM (ansm.sante.fr, July 2, 2026); VIDAL.fr (July 2, 2026); AFP/actualites-sante.com (July 3, 2026). Biologic Classification Dispute — Seventh Circuit (August 2026): A federal court vacated the FDA's classification of retatrutide as a "drug" in September 2025 and remanded the question to the agency. Eli Lilly appealed to the Seventh Circuit Court of Appeals in February 2026, asking that retatrutide be classified as a biological product outright. Oral arguments before the Seventh Circuit are scheduled for September 24, 2026. The distinction is legally significant: a biologic classification would entitle Lilly to 12 years of exclusivity under the Biologics Price Competition and Innovation Act — longer than the standard 5-year New Chemical Entity exclusivity available for small-molecule drugs — and would permanently foreclose any compounding access, as biologics cannot be placed on the 503A or 503B Bulks Lists. The FDA's remand analysis (now required regardless of the court outcome) will also establish a binding standard for what makes a peptide "analogous to a protein," which may affect the classification of other large peptide therapeutics in development. No court ruling has been issued as of August 21, 2026. Sources: thepeptidetoolkit.com (May 21, 2026); compoundprotocol.com (August 11, 2026); BioSpace (August 5, 2026). TGA Safety Alert — Australia (September 14, 2026): Australia's Therapeutic Goods Administration issued a public safety warning after a patient suffered a torn oesophagus requiring hospitalisation following use of a product sold as retatrutide. Laboratory analysis confirmed the vial contained no retatrutide — instead it held a high and undeclared dose of semaglutide, consistent with deliberate counterfeiting. The TGA warns that illicit peptide products sold online — including those labelled as retatrutide — may be mislabelled, contaminated, or contain entirely different active substances. Consumers who experienced severe vomiting or GI symptoms after using such products are advised to seek immediate medical attention. Retatrutide is not approved by the TGA or any regulatory authority. The incident underscores the serious injury risk from counterfeit and unapproved injectable peptides obtained outside authorised clinical trial channels. Sources: ABC News Australia (abc.net.au, September 14, 2026); The Guardian Australia (theguardian.com, September 14, 2026); pharmex.co (September 14, 2026).

Regulatory Notice (May 2026): The FDA proposed on April 30, 2026 to remove Semaglutide and Tirzepatide from the 503B compounding bulks list. The national shortage designation has been resolved. Compounded versions of these compounds may face legal restrictions. Verify current FDA compounding status in your region before sourcing.

Regulatory Notice (August 2026 — SYNCHRONIZE-1 UPDATED): Survodutide is not FDA approved. SYNCHRONIZE-1 Phase 3 primary results announced April 28, 2026: survodutide met both co-primary endpoints (efficacy and treatment-regimen estimands), with the higher dose achieving 16.6% mean total body weight loss at 76 weeks in adults with obesity without diabetes. ADA 2026 sub-analysis (June 8, 2026) confirmed 34% visceral fat reduction and 63% liver fat reduction at 48 weeks (LIVERAGE NASH/MASH trial). The drug has FDA Breakthrough Therapy designation for MASH with moderate-to-advanced fibrosis. SYNCHRONIZE-2 (type 2 diabetes + obesity) results expected H2 2026. NDA filing projected 2027; approval not before 2027. Survodutide is a dual GLP-1/glucagon receptor agonist, distinct from GLP-1-only agents (semaglutide, tirzepatide). Not on the 503A or 503B bulk drug substances list. Sources: Boehringer Ingelheim press release April 28, 2026 (boehringer-ingelheim.com); BioPharma International June 7, 2026; Fierce Biotech June 8, 2026.

Regulatory Notice (July 2026): CagriSema (cagrilintide + semaglutide) NDA filed with the FDA on December 18, 2025 (Novo Nordisk). FDA decision expected Q4 2026 (PDUFA target date: December 31, 2026 — confirmed per FDA acceptance and Novo Nordisk investor disclosure as of September 2, 2026; source: pdufa.bio/pdufa/NVO-cagrisema, September 2, 2026). REDEFINE 1 Phase 3: 22.7% weight loss at 68 weeks. REDEFINE 4 (head-to-head vs. tirzepatide): 23.0% vs. 25.5% — did not achieve non-inferiority. Cagrilintide alone and CagriSema blend are not FDA approved. Research compounds pending approval decision. Fifth Circuit Court of Appeals — GLP-1 Compounding Ruling (August 27, 2026): On August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit affirmed two lower-court judgments upholding the FDA's removal of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) from the national drug shortage list. Because federal law (21 U.S.C. § 353a/353b) only permits compounding copies of an approved drug while it remains in shortage, this ruling removes the shortage-based legal basis for bulk compounding of these agents. 503A patient-specific compounding for individual patients with documented medical needs remains a separate, narrower pathway. 503B outsourcing facility bulk production of essentially-equivalent copies is no longer supported by a shortage justification. The ruling does not affect the separate FDA rulemaking (503B exclusion proposal, April 30, 2026) which is still under agency review. Sources: teleranked.com (August 27, 2026); peptidesbeat.com (August 27, 2026); courthousenews.com. FDA Import Alert 66-80 — GLP-1 API Detention (August 21, 2026): On August 21, 2026, the FDA published a major revision to Import Alert 66-80, authorising Detention Without Physical Examination (DWPE) of foreign-sourced GLP-1 receptor agonist bulk drug substances — including semaglutide, tirzepatide, liraglutide, exenatide, dulaglutide, and related peptide APIs — at U.S. ports of entry. The alert accompanies the FDA's "green list" program: manufacturers that have passed FDA inspection and cGMP review can apply to be exempted from automatic detention. Facilities that have not responded to FDA inspection requests or have been found non-compliant remain subject to DWPE. Practically, this means bulk GLP-1 API imported from foreign sources without green-list status can be detained and refused entry without individual inspection. This is a supply-chain enforcement tool targeting the import of raw GLP-1 peptide APIs used in compounding; it does not change whether compounding is otherwise permitted. The alert operates in parallel with the ongoing 503B exclusion rulemaking (comment period closed July 30, 2026, final rule pending) and the Fifth Circuit ruling (August 27, 2026) upholding removal of these agents from shortage status. Source: FDA Import Alert 66-80, accessdata.fda.gov (August 21, 2026); FDA press announcement (fda.gov); Frier Levitt (frierlevitt.com); PeptideKnow.com.

Regulatory Notice (August 2026 — INVESTIGATIONAL): Zenagamtide (formerly amycretin, NN9487) is an investigational compound developed by Novo Nordisk. It is not FDA approved and is not available for use outside authorised clinical trials. Two Phase 2 trials published in The Lancet on August 15, 2026 (PMID 42532080 — subcutaneous; PIIS0140-6736(26)01247-X — oral) confirm Phase 2 dose-finding data in type 2 diabetes. Phase 3 programs (AMAZE for obesity; AMBITION for T2D) announced for H2 2026 initiation. No compounding pathway exists for investigational compounds. Sources: The Lancet (August 15, 2026, PMID 42532080); Novo Nordisk Q2 2026 investor presentation; ADA 2026 Scientific Sessions.

Regulatory Notice (September 2026 — FDA Enforcement): On August 24, 2026, the FDA issued warning letters to five online peptide vendors — NuScience Peptides LLC, Royal Peptides LLC, Peak Performance Peptides, Peptide Partners LLC, and TXP Innovations LLC dba Tex Peptides — citing Tesamorelin as an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act. Note: FDA-approved Egrifta SV (tesamorelin) is approved for HIV-related lipodystrophy, but research-use tesamorelin sold by these vendors outside that approved indication is unapproved. The letters were published on FDA.gov on September 1, 2026, and give recipients 15 days to respond. Sources: FDA warning letters (fda.gov, August 24, 2026): Peak Performance Peptides #735127; pharmaphorum (September 2, 2026).

Regulatory Notice (September 2026 — FDA Enforcement): On August 24, 2026, the FDA issued warning letters to five online peptide vendors — NuScience Peptides LLC, Royal Peptides LLC, Peak Performance Peptides, Peptide Partners LLC, and TXP Innovations LLC dba Tex Peptides — citing Tesamorelin as an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act. Note: FDA-approved Egrifta SV (tesamorelin) is approved for HIV-related lipodystrophy, but research-use tesamorelin sold by these vendors outside that approved indication is unapproved. The letters were published on FDA.gov on September 1, 2026, and give recipients 15 days to respond. Sources: FDA warning letters (fda.gov, August 24, 2026): Peak Performance Peptides #735127; pharmaphorum (September 2, 2026).

Regulatory Notice:TGA Notice (June 2026): Australia's Therapeutic Goods Administration formally designated unapproved peptide products — including Ipamorelin — as a 2026 compliance enforcement priority (TGA media release, June 10, 2026). These compounds are not registered therapeutic goods in Australia; they may not be lawfully imported, supplied, or advertised for human therapeutic use. Source: tga.gov.au/news/media-releases/tga-strengthens-compliance-focus-unapproved-peptide-products. TGA Escalation (July 20, 2026): The TGA wrote directly to social media and e-commerce platforms to halt unlawful advertising, and issued formal notices to peptide promoters and suppliers stating: 'If you are unlawfully importing, manufacturing, advertising or supplying unapproved peptide products, expect the TGA to take action.' This marks a shift from consumer education to active enforcement against supply-side operators. Source: TGA media release, July 20, 2026 (tga.gov.au). TGA Active Enforcement (August 4, 2026): TGA officers and NSW Police executed search warrants at two residential properties in New South Wales on August 4, 2026, seizing more than $120,000 worth of illicit peptide and anabolic steroid products. The properties were linked to a social media influencer who had previously been warned by the TGA for importing, relabelling, advertising, and supplying unapproved peptide products — a pattern of supply-side enforcement now escalating beyond warnings to physical raids. Source: TGA media release, tga.gov.au (August 17, 2026).

Regulatory Notice (July 2026): ANSM Safety Alert — France (July 2, 2026): France's national medicines regulatory agency (ANSM) published a formal public safety alert titled 'Peptides vendus en ligne: ne les utilisez pas, ils peuvent être dangereux' (Peptides sold online: do not use them, they can be dangerous). The alert cites pharmacovigilance reports of serious adverse events — including hospitalizations — in individuals aged 15 to 35 following use of injectable peptides purchased online, including retatrutide, BPC-157, TB-500, GHK-Cu, NAD+, and growth hormone products. The ANSM states that these compounds are not authorized or evaluated for human use in France, warns that products sold informally (online, social media, peer networks) are not subject to quality or safety controls, and flags a potential cancer-progression risk from unregulated cell-growth stimulants. The ANSM strongly advises the French public not to acquire or use these compounds. This alert does not affect the research-use legal status of these compounds globally but confirms that EU-member regulators are actively monitoring and taking enforcement action on the supply side. Source: ANSM (ansm.sante.fr, July 2, 2026); VIDAL.fr (July 2, 2026); AFP/actualites-sante.com (July 3, 2026).

Regulatory Notice (July 24, 2026 — PCAC VOTE OUTCOME): On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted 8–6 in favor of recommending BPC-157 for inclusion on the 503A Bulk Drug Substances List — overriding the FDA staff's own recommendation against it. This is an advisory recommendation only; it does not immediately authorize compounding. The FDA must now initiate formal Federal Register rulemaking (typically 12–24 months) before compounding pharmacies can legally prepare BPC-157 under a prescriber relationship. The RUO (research use only) grey-market pathway remains legally unchanged. TGA Notice (June 2026): Australia's TGA designated unapproved peptide products including BPC-157 as a 2026 compliance enforcement priority. Not registered in Australia; may not be lawfully imported, supplied, or advertised for human therapeutic use. TGA Escalation (July 20, 2026): The TGA wrote directly to social media and e-commerce platforms to halt unlawful advertising, and issued formal notices to peptide promoters and suppliers stating: 'If you are unlawfully importing, manufacturing, advertising or supplying unapproved peptide products, expect the TGA to take action.' This marks a shift from consumer education to active enforcement against supply-side operators. Source: TGA media release, July 20, 2026 (tga.gov.au). Sources: ABCNews (July 23, 2026); NPR (July 23, 2026); FDA.gov PCAC July 23-24 meeting. TGA Active Enforcement (August 4, 2026): TGA officers and NSW Police executed search warrants at two residential properties in New South Wales on August 4, 2026, seizing more than $120,000 worth of illicit peptide and anabolic steroid products. The properties were linked to a social media influencer who had previously been warned by the TGA for importing, relabelling, advertising, and supplying unapproved peptide products — a pattern of supply-side enforcement now escalating beyond warnings to physical raids. Source: TGA media release, tga.gov.au (August 17, 2026). ANSM Safety Alert — France (July 2, 2026): France's national medicines regulatory agency (ANSM) published a formal public safety alert titled 'Peptides vendus en ligne: ne les utilisez pas, ils peuvent être dangereux' (Peptides sold online: do not use them, they can be dangerous). The alert cites pharmacovigilance reports of serious adverse events — including hospitalizations — in individuals aged 15 to 35 following use of injectable peptides purchased online, including retatrutide, BPC-157, TB-500, GHK-Cu, NAD+, and growth hormone products. The ANSM states that these compounds are not authorized or evaluated for human use in France, warns that products sold informally (online, social media, peer networks) are not subject to quality or safety controls, and flags a potential cancer-progression risk from unregulated cell-growth stimulants. The ANSM strongly advises the French public not to acquire or use these compounds. This alert does not affect the research-use legal status of these compounds globally but confirms that EU-member regulators are actively monitoring and taking enforcement action on the supply side. Source: ANSM (ansm.sante.fr, July 2, 2026); VIDAL.fr (July 2, 2026); AFP/actualites-sante.com (July 3, 2026). Health Canada Enforcement — Canada (July 29, 2026): On June 11, 2026, the Superior Court of Québec granted Health Canada a permanent injunction against Canlab Research and its representatives, permanently barring the company from selling or promoting unauthorized injectable peptides in Canada. Health Canada announced the injunction publicly on July 29, 2026. Injectable peptides are regulated as prescription drugs in Canada and may not be lawfully sold without authorization. Source: Health Canada news release (canada.ca/en/health-canada, July 29, 2026); CityNews Montreal (July 29, 2026); Mondaq (August 20, 2026).

Regulatory Notice (July 24, 2026 — PCAC VOTE OUTCOME): On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted 8–6 in favor of recommending BPC-157 for inclusion on the 503A Bulk Drug Substances List — overriding the FDA staff's own recommendation against it. This is an advisory recommendation only; it does not immediately authorize compounding. The FDA must now initiate formal Federal Register rulemaking (typically 12–24 months) before compounding pharmacies can legally prepare BPC-157 under a prescriber relationship. The RUO (research use only) grey-market pathway remains legally unchanged. TGA Notice (June 2026): Australia's TGA designated unapproved peptide products including BPC-157 as a 2026 compliance enforcement priority. Not registered in Australia; may not be lawfully imported, supplied, or advertised for human therapeutic use. TGA Escalation (July 20, 2026): The TGA wrote directly to social media and e-commerce platforms to halt unlawful advertising, and issued formal notices to peptide promoters and suppliers stating: 'If you are unlawfully importing, manufacturing, advertising or supplying unapproved peptide products, expect the TGA to take action.' This marks a shift from consumer education to active enforcement against supply-side operators. Source: TGA media release, July 20, 2026 (tga.gov.au). Sources: ABCNews (July 23, 2026); NPR (July 23, 2026); FDA.gov PCAC July 23-24 meeting. TGA Active Enforcement (August 4, 2026): TGA officers and NSW Police executed search warrants at two residential properties in New South Wales on August 4, 2026, seizing more than $120,000 worth of illicit peptide and anabolic steroid products. The properties were linked to a social media influencer who had previously been warned by the TGA for importing, relabelling, advertising, and supplying unapproved peptide products — a pattern of supply-side enforcement now escalating beyond warnings to physical raids. Source: TGA media release, tga.gov.au (August 17, 2026). ANSM Safety Alert — France (July 2, 2026): France's national medicines regulatory agency (ANSM) published a formal public safety alert titled 'Peptides vendus en ligne: ne les utilisez pas, ils peuvent être dangereux' (Peptides sold online: do not use them, they can be dangerous). The alert cites pharmacovigilance reports of serious adverse events — including hospitalizations — in individuals aged 15 to 35 following use of injectable peptides purchased online, including retatrutide, BPC-157, TB-500, GHK-Cu, NAD+, and growth hormone products. The ANSM states that these compounds are not authorized or evaluated for human use in France, warns that products sold informally (online, social media, peer networks) are not subject to quality or safety controls, and flags a potential cancer-progression risk from unregulated cell-growth stimulants. The ANSM strongly advises the French public not to acquire or use these compounds. This alert does not affect the research-use legal status of these compounds globally but confirms that EU-member regulators are actively monitoring and taking enforcement action on the supply side. Source: ANSM (ansm.sante.fr, July 2, 2026); VIDAL.fr (July 2, 2026); AFP/actualites-sante.com (July 3, 2026). Health Canada Enforcement — Canada (July 29, 2026): On June 11, 2026, the Superior Court of Québec granted Health Canada a permanent injunction against Canlab Research and its representatives, permanently barring the company from selling or promoting unauthorized injectable peptides in Canada. Health Canada announced the injunction publicly on July 29, 2026. Injectable peptides are regulated as prescription drugs in Canada and may not be lawfully sold without authorization. Source: Health Canada news release (canada.ca/en/health-canada, July 29, 2026); CityNews Montreal (July 29, 2026); Mondaq (August 20, 2026).

Regulatory Notice (July 24, 2026 — PCAC VOTE OUTCOME): On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted in favor of recommending TB-500 for inclusion on the 503A Bulk Drug Substances List — overriding the FDA staff's own recommendation against it. This is an advisory recommendation only; formal FDA rulemaking (typically 12–24 months) is required before compounding pharmacies can legally prepare TB-500. TGA Notice (June 2026): Australia's TGA designated unapproved peptide products including TB-500 as a 2026 compliance enforcement priority. Not registered in Australia; may not be lawfully imported, supplied, or advertised for human therapeutic use. TGA Escalation (July 20, 2026): The TGA wrote directly to social media and e-commerce platforms to halt unlawful advertising, and issued formal notices to peptide promoters and suppliers stating: 'If you are unlawfully importing, manufacturing, advertising or supplying unapproved peptide products, expect the TGA to take action.' This marks a shift from consumer education to active enforcement against supply-side operators. Source: TGA media release, July 20, 2026 (tga.gov.au). Sources: MarketWatch (July 23, 2026); NPR (July 23, 2026); FDA.gov PCAC July 23-24 meeting. TGA Active Enforcement (August 4, 2026): TGA officers and NSW Police executed search warrants at two residential properties in New South Wales on August 4, 2026, seizing more than $120,000 worth of illicit peptide and anabolic steroid products. The properties were linked to a social media influencer who had previously been warned by the TGA for importing, relabelling, advertising, and supplying unapproved peptide products — a pattern of supply-side enforcement now escalating beyond warnings to physical raids. Source: TGA media release, tga.gov.au (August 17, 2026). ANSM Safety Alert — France (July 2, 2026): France's national medicines regulatory agency (ANSM) published a formal public safety alert titled 'Peptides vendus en ligne: ne les utilisez pas, ils peuvent être dangereux' (Peptides sold online: do not use them, they can be dangerous). The alert cites pharmacovigilance reports of serious adverse events — including hospitalizations — in individuals aged 15 to 35 following use of injectable peptides purchased online, including retatrutide, BPC-157, TB-500, GHK-Cu, NAD+, and growth hormone products. The ANSM states that these compounds are not authorized or evaluated for human use in France, warns that products sold informally (online, social media, peer networks) are not subject to quality or safety controls, and flags a potential cancer-progression risk from unregulated cell-growth stimulants. The ANSM strongly advises the French public not to acquire or use these compounds. This alert does not affect the research-use legal status of these compounds globally but confirms that EU-member regulators are actively monitoring and taking enforcement action on the supply side. Source: ANSM (ansm.sante.fr, July 2, 2026); VIDAL.fr (July 2, 2026); AFP/actualites-sante.com (July 3, 2026). Health Canada Enforcement — Canada (July 29, 2026): On June 11, 2026, the Superior Court of Québec granted Health Canada a permanent injunction against Canlab Research and its representatives, permanently barring the company from selling or promoting unauthorized injectable peptides in Canada. Health Canada announced the injunction publicly on July 29, 2026. Injectable peptides are regulated as prescription drugs in Canada and may not be lawfully sold without authorization. Source: Health Canada news release (canada.ca/en/health-canada, July 29, 2026); CityNews Montreal (July 29, 2026); Mondaq (August 20, 2026).

Regulatory Notice (July 24, 2026 — PCAC VOTE OUTCOME): On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted in favor of recommending TB-500 for inclusion on the 503A Bulk Drug Substances List — overriding the FDA staff's own recommendation against it. This is an advisory recommendation only; formal FDA rulemaking (typically 12–24 months) is required before compounding pharmacies can legally prepare TB-500. TGA Notice (June 2026): Australia's TGA designated unapproved peptide products including TB-500 as a 2026 compliance enforcement priority. Not registered in Australia; may not be lawfully imported, supplied, or advertised for human therapeutic use. TGA Escalation (July 20, 2026): The TGA wrote directly to social media and e-commerce platforms to halt unlawful advertising, and issued formal notices to peptide promoters and suppliers stating: 'If you are unlawfully importing, manufacturing, advertising or supplying unapproved peptide products, expect the TGA to take action.' This marks a shift from consumer education to active enforcement against supply-side operators. Source: TGA media release, July 20, 2026 (tga.gov.au). Sources: MarketWatch (July 23, 2026); NPR (July 23, 2026); FDA.gov PCAC July 23-24 meeting. TGA Active Enforcement (August 4, 2026): TGA officers and NSW Police executed search warrants at two residential properties in New South Wales on August 4, 2026, seizing more than $120,000 worth of illicit peptide and anabolic steroid products. The properties were linked to a social media influencer who had previously been warned by the TGA for importing, relabelling, advertising, and supplying unapproved peptide products — a pattern of supply-side enforcement now escalating beyond warnings to physical raids. Source: TGA media release, tga.gov.au (August 17, 2026). ANSM Safety Alert — France (July 2, 2026): France's national medicines regulatory agency (ANSM) published a formal public safety alert titled 'Peptides vendus en ligne: ne les utilisez pas, ils peuvent être dangereux' (Peptides sold online: do not use them, they can be dangerous). The alert cites pharmacovigilance reports of serious adverse events — including hospitalizations — in individuals aged 15 to 35 following use of injectable peptides purchased online, including retatrutide, BPC-157, TB-500, GHK-Cu, NAD+, and growth hormone products. The ANSM states that these compounds are not authorized or evaluated for human use in France, warns that products sold informally (online, social media, peer networks) are not subject to quality or safety controls, and flags a potential cancer-progression risk from unregulated cell-growth stimulants. The ANSM strongly advises the French public not to acquire or use these compounds. This alert does not affect the research-use legal status of these compounds globally but confirms that EU-member regulators are actively monitoring and taking enforcement action on the supply side. Source: ANSM (ansm.sante.fr, July 2, 2026); VIDAL.fr (July 2, 2026); AFP/actualites-sante.com (July 3, 2026). Health Canada Enforcement — Canada (July 29, 2026): On June 11, 2026, the Superior Court of Québec granted Health Canada a permanent injunction against Canlab Research and its representatives, permanently barring the company from selling or promoting unauthorized injectable peptides in Canada. Health Canada announced the injunction publicly on July 29, 2026. Injectable peptides are regulated as prescription drugs in Canada and may not be lawfully sold without authorization. Source: Health Canada news release (canada.ca/en/health-canada, July 29, 2026); CityNews Montreal (July 29, 2026); Mondaq (August 20, 2026).

Regulatory Notice:TGA Notice (June 2026): Australia's Therapeutic Goods Administration formally designated unapproved peptide products — including BPC-157 and TB-500 — as 2026 compliance enforcement priorities (TGA media release, June 10, 2026). These compounds are not registered therapeutic goods in Australia; they may not be lawfully imported, supplied, or advertised for human therapeutic use. Source: tga.gov.au/news/media-releases/tga-strengthens-compliance-focus-unapproved-peptide-products. Update (July 23–24, 2026): PCAC voted to recommend this compound for inclusion on the 503A Bulk Drug Substances List, overriding the FDA staff recommendation. A favorable PCAC recommendation is not FDA approval and does not immediately authorize compounding — formal notice-and-comment rulemaking (typically 12–24 months) must conclude before 503A compounding pharmacies may legally prepare this compound. The FDA is not bound by the advisory vote. Source: FDA.gov/advisory-committees (July 23–24, 2026 PCAC meeting); NPR (July 23, 2026); NYT (July 24, 2026). TGA Escalation (July 20, 2026): The TGA wrote directly to social media and e-commerce platforms to halt unlawful advertising, and issued formal notices to peptide promoters and suppliers stating: 'If you are unlawfully importing, manufacturing, advertising or supplying unapproved peptide products, expect the TGA to take action.' This marks a shift from consumer education to active enforcement against supply-side operators. Source: TGA media release, July 20, 2026 (tga.gov.au). TGA Active Enforcement (August 4, 2026): TGA officers and NSW Police executed search warrants at two residential properties in New South Wales on August 4, 2026, seizing more than $120,000 worth of illicit peptide and anabolic steroid products. The properties were linked to a social media influencer who had previously been warned by the TGA for importing, relabelling, advertising, and supplying unapproved peptide products — a pattern of supply-side enforcement now escalating beyond warnings to physical raids. Source: TGA media release, tga.gov.au (August 17, 2026). ANSM Safety Alert — France (July 2, 2026): France's national medicines regulatory agency (ANSM) published a formal public safety alert titled 'Peptides vendus en ligne: ne les utilisez pas, ils peuvent être dangereux' (Peptides sold online: do not use them, they can be dangerous). The alert cites pharmacovigilance reports of serious adverse events — including hospitalizations — in individuals aged 15 to 35 following use of injectable peptides purchased online, including retatrutide, BPC-157, TB-500, GHK-Cu, NAD+, and growth hormone products. The ANSM states that these compounds are not authorized or evaluated for human use in France, warns that products sold informally (online, social media, peer networks) are not subject to quality or safety controls, and flags a potential cancer-progression risk from unregulated cell-growth stimulants. The ANSM strongly advises the French public not to acquire or use these compounds. This alert does not affect the research-use legal status of these compounds globally but confirms that EU-member regulators are actively monitoring and taking enforcement action on the supply side. Source: ANSM (ansm.sante.fr, July 2, 2026); VIDAL.fr (July 2, 2026); AFP/actualites-sante.com (July 3, 2026).

Regulatory Notice:TGA Notice (June 2026): Australia's Therapeutic Goods Administration formally designated unapproved peptide products — including BPC-157 and TB-500 — as a 2026 compliance enforcement priority (TGA media release, June 10, 2026). These compounds are not registered therapeutic goods in Australia; they may not be lawfully imported, supplied, or advertised for human therapeutic use. Source: tga.gov.au/news/media-releases/tga-strengthens-compliance-focus-unapproved-peptide-products. Update (July 23–24, 2026): PCAC voted to recommend this compound for inclusion on the 503A Bulk Drug Substances List, overriding the FDA staff recommendation. A favorable PCAC recommendation is not FDA approval and does not immediately authorize compounding — formal notice-and-comment rulemaking (typically 12–24 months) must conclude before 503A compounding pharmacies may legally prepare this compound. The FDA is not bound by the advisory vote. Source: FDA.gov/advisory-committees (July 23–24, 2026 PCAC meeting); NPR (July 23, 2026); NYT (July 24, 2026). TGA Escalation (July 20, 2026): The TGA wrote directly to social media and e-commerce platforms to halt unlawful advertising, and issued formal notices to peptide promoters and suppliers stating: 'If you are unlawfully importing, manufacturing, advertising or supplying unapproved peptide products, expect the TGA to take action.' This marks a shift from consumer education to active enforcement against supply-side operators. Source: TGA media release, July 20, 2026 (tga.gov.au). TGA Active Enforcement (August 4, 2026): TGA officers and NSW Police executed search warrants at two residential properties in New South Wales on August 4, 2026, seizing more than $120,000 worth of illicit peptide and anabolic steroid products. The properties were linked to a social media influencer who had previously been warned by the TGA for importing, relabelling, advertising, and supplying unapproved peptide products — a pattern of supply-side enforcement now escalating beyond warnings to physical raids. Source: TGA media release, tga.gov.au (August 17, 2026). ANSM Safety Alert — France (July 2, 2026): France's national medicines regulatory agency (ANSM) published a formal public safety alert titled 'Peptides vendus en ligne: ne les utilisez pas, ils peuvent être dangereux' (Peptides sold online: do not use them, they can be dangerous). The alert cites pharmacovigilance reports of serious adverse events — including hospitalizations — in individuals aged 15 to 35 following use of injectable peptides purchased online, including retatrutide, BPC-157, TB-500, GHK-Cu, NAD+, and growth hormone products. The ANSM states that these compounds are not authorized or evaluated for human use in France, warns that products sold informally (online, social media, peer networks) are not subject to quality or safety controls, and flags a potential cancer-progression risk from unregulated cell-growth stimulants. The ANSM strongly advises the French public not to acquire or use these compounds. This alert does not affect the research-use legal status of these compounds globally but confirms that EU-member regulators are actively monitoring and taking enforcement action on the supply side. Source: ANSM (ansm.sante.fr, July 2, 2026); VIDAL.fr (July 2, 2026); AFP/actualites-sante.com (July 3, 2026). Health Canada Enforcement — Canada (July 29, 2026): On June 11, 2026, the Superior Court of Québec granted Health Canada a permanent injunction against Canlab Research and its representatives, permanently barring the company from selling or promoting unauthorized injectable peptides in Canada. Health Canada announced the injunction publicly on July 29, 2026. Injectable peptides are regulated as prescription drugs in Canada and may not be lawfully sold without authorization. Source: Health Canada news release (canada.ca/en/health-canada, July 29, 2026); CityNews Montreal (July 29, 2026); Mondaq (August 20, 2026).

Regulatory Notice (July 24, 2026 — PCAC VOTE OUTCOME): On July 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted in favor of recommending Epithalon for inclusion on the 503A Bulk Drug Substances List (7–5 vote, 1 abstention) — overriding the FDA staff's own recommendation against it. This is an advisory recommendation only; formal FDA rulemaking (typically 12–24 months) is required before compounding pharmacies can legally prepare Epithalon. Sources: peptidedossier.com PCAC summary; FDA.gov PCAC July 23-24 meeting.

Regulatory Notice (July 24, 2026 — PCAC VOTE OUTCOME): On July 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted in favor of recommending Epithalon for inclusion on the 503A Bulk Drug Substances List (7–5 vote, 1 abstention) — overriding the FDA staff's own recommendation against it. This is an advisory recommendation only; formal FDA rulemaking (typically 12–24 months) is required before compounding pharmacies can legally prepare Epithalon. Sources: peptidedossier.com PCAC summary; FDA.gov PCAC July 23-24 meeting.

Regulatory Notice (July 2026): ANSM Safety Alert — France (July 2, 2026): France's national medicines regulatory agency (ANSM) published a formal public safety alert titled 'Peptides vendus en ligne: ne les utilisez pas, ils peuvent être dangereux' (Peptides sold online: do not use them, they can be dangerous). The alert cites pharmacovigilance reports of serious adverse events — including hospitalizations — in individuals aged 15 to 35 following use of injectable peptides purchased online, including retatrutide, BPC-157, TB-500, GHK-Cu, NAD+, and growth hormone products. The ANSM states that these compounds are not authorized or evaluated for human use in France, warns that products sold informally (online, social media, peer networks) are not subject to quality or safety controls, and flags a potential cancer-progression risk from unregulated cell-growth stimulants. The ANSM strongly advises the French public not to acquire or use these compounds. This alert does not affect the research-use legal status of these compounds globally but confirms that EU-member regulators are actively monitoring and taking enforcement action on the supply side. Source: ANSM (ansm.sante.fr, July 2, 2026); VIDAL.fr (July 2, 2026); AFP/actualites-sante.com (July 3, 2026).

Regulatory Notice (July 24, 2026 — PCAC VOTE OUTCOME): On July 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted in favor of recommending Semax for inclusion on the 503A Bulk Drug Substances List (8–5 vote, 1 abstention) — overriding the FDA staff's own recommendation against it. This is an advisory recommendation only; formal FDA rulemaking (typically 12–24 months) is required before compounding pharmacies can legally prepare Semax. Sources: peptidedossier.com PCAC summary; FDA.gov PCAC July 23-24 meeting.

Regulatory Notice (July 24, 2026 — PCAC VOTE OUTCOME): On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted in favor of recommending MOTS-c for inclusion on the 503A Bulk Drug Substances List (7–5 vote, 2 abstentions) — overriding the FDA staff's own recommendation against it. This is an advisory recommendation only; formal FDA rulemaking (typically 12–24 months) is required before compounding pharmacies can legally prepare MOTS-c. Sources: MarketWatch (July 23, 2026); NPR (July 23, 2026); FDA.gov PCAC July 23-24 meeting.

Regulatory Notice (September 2026 — FDA Enforcement): On August 24, 2026, the FDA issued warning letters to five online peptide vendors — NuScience Peptides LLC, Royal Peptides LLC, Peak Performance Peptides, Peptide Partners LLC, and TXP Innovations LLC dba Tex Peptides — citing SS-31 (Elamipretide) as an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act. The letters were published on FDA.gov on September 1, 2026, and give recipients 15 days to respond. SS-31 is not FDA-approved, may not be lawfully marketed or sold as a drug product, and cannot be compounded under 503A or 503B. Sources: FDA warning letters (fda.gov, August 24, 2026): NuScience Peptides #733652; Peptide Partners #735063; Peak Performance Peptides #735127; pharmaphorum (September 2, 2026).

Regulatory Notice (July 24, 2026 — PCAC VOTE OUTCOME): On July 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted against recommending Emideltide (DSIP) for inclusion on the 503A Bulk Drug Substances List. The committee cited insufficient evidence of clinical need and the availability of already-approved treatments for the indicated conditions (opioid withdrawal, chronic insomnia, narcolepsy). DSIP/Emideltide remains ineligible for 503A compounding. Sources: NYT (July 24, 2026); peptidedossier.com PCAC summary; FDA.gov PCAC July 23-24 meeting.

Regulatory Notice (September 2026 — FDA Enforcement): On August 24, 2026, the FDA issued warning letters to five online peptide vendors — NuScience Peptides LLC, Royal Peptides LLC, Peak Performance Peptides, Peptide Partners LLC, and TXP Innovations LLC dba Tex Peptides — citing PT-141 (Bremelanotide) as an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act. Note: FDA-approved Vyleesi (bremelanotide) exists for hypoactive sexual desire disorder in premenopausal women (approved 2019), but the compounded/research-use versions of PT-141 sold by these vendors are unapproved. The letters were published on FDA.gov on September 1, 2026, and give recipients 15 days to respond. Research-use PT-141 cannot be legally marketed as a drug product. Sources: FDA warning letters (fda.gov, August 24, 2026): Peptide Partners #735063; Peak Performance Peptides #735127; pharmaphorum (September 2, 2026).

Regulatory Notice (September 2026 — FDA Enforcement): On August 24, 2026, the FDA issued warning letters to five online peptide vendors — NuScience Peptides LLC, Royal Peptides LLC, Peak Performance Peptides, Peptide Partners LLC, and TXP Innovations LLC dba Tex Peptides — citing PT-141 (Bremelanotide) as an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act. Note: FDA-approved Vyleesi (bremelanotide) exists for hypoactive sexual desire disorder in premenopausal women (approved 2019), but the compounded/research-use versions of PT-141 sold by these vendors are unapproved. The letters were published on FDA.gov on September 1, 2026, and give recipients 15 days to respond. Research-use PT-141 cannot be legally marketed as a drug product. Sources: FDA warning letters (fda.gov, August 24, 2026): Peptide Partners #735063; Peak Performance Peptides #735127; pharmaphorum (September 2, 2026).

Regulatory Notice (August 2026): Melanotan II was removed from the FDA Category 2 "Do Not Compound" list on April 15, 2026, following withdrawal of the original nomination. Removal from Category 2 does not authorize compounding — formal FDA rulemaking is still required. Update (August 2026): The FDA has confirmed a second PCAC hearing will convene on or before February 28, 2027 to evaluate Melanotan II, LL-37, injectable GHK-Cu, Dihexa, and PEG-MGF for the 503A Bulk Drug Substances List. Melanotan II remains off the 503A Bulks List pending that review. TGA Notice (June 2026): Australia's Therapeutic Goods Administration formally designated unapproved peptide products — including Melanotan II — as a 2026 compliance enforcement priority. These compounds are not registered therapeutic goods in Australia; they may not be lawfully imported, supplied, or advertised for human therapeutic use. Sources: FDA.gov; tga.gov.au (June 10, 2026); peptideknow.com (PCAC second tranche, July 2026). TGA Active Enforcement (August 4, 2026): TGA officers and NSW Police executed search warrants at two residential properties in New South Wales on August 4, 2026, seizing more than $120,000 worth of illicit peptide and anabolic steroid products. The properties were linked to a social media influencer who had previously been warned by the TGA for importing, relabelling, advertising, and supplying unapproved peptide products — a pattern of supply-side enforcement now escalating beyond warnings to physical raids. Source: TGA media release, tga.gov.au (August 17, 2026). TGA Dosing Safety Alert (August 17, 2026): The TGA published a formal safety alert — "Melanotan II tanning peptide products found to be inconsistently dosed" — after laboratory testing of seized products revealed extreme dosing variance. Testing of five bottles of a nasal spray labelled "Pure Tans Triple Strength 30 MG" showed the estimated amount of Melanotan II varied from 22mg to 54mg per bottle — representing a more than 2× range within products carrying the same label. The TGA also announced it had issued 27 infringement notices totalling AUD$101,412 to a NSW-based individual for the alleged unlawful supply of Melanotan II to Australian consumers. Infringement notices were paid in May 2026. The alert underscores that unregulated Melanotan II products are prescription-only medicines in Australia, carry serious health risks, and may not contain the amount stated on the label. Source: TGA safety alert (tga.gov.au, August 17, 2026); 7News (August 17, 2026); TGA media release on individual issued 27 infringement notices (tga.gov.au).

Regulatory Notice (August 2026): Melanotan II was removed from the FDA Category 2 "Do Not Compound" list on April 15, 2026, following withdrawal of the original nomination. Removal from Category 2 does not authorize compounding — formal FDA rulemaking is still required. Update (August 2026): The FDA has confirmed a second PCAC hearing will convene on or before February 28, 2027 to evaluate Melanotan II, LL-37, injectable GHK-Cu, Dihexa, and PEG-MGF for the 503A Bulk Drug Substances List. Melanotan II remains off the 503A Bulks List pending that review. TGA Notice (June 2026): Australia's Therapeutic Goods Administration formally designated unapproved peptide products — including Melanotan II — as a 2026 compliance enforcement priority. These compounds are not registered therapeutic goods in Australia; they may not be lawfully imported, supplied, or advertised for human therapeutic use. Sources: FDA.gov; tga.gov.au (June 10, 2026); peptideknow.com (PCAC second tranche, July 2026). TGA Active Enforcement (August 4, 2026): TGA officers and NSW Police executed search warrants at two residential properties in New South Wales on August 4, 2026, seizing more than $120,000 worth of illicit peptide and anabolic steroid products. The properties were linked to a social media influencer who had previously been warned by the TGA for importing, relabelling, advertising, and supplying unapproved peptide products — a pattern of supply-side enforcement now escalating beyond warnings to physical raids. Source: TGA media release, tga.gov.au (August 17, 2026). Regulatory Notice (August 2026): Melanotan II was removed from the FDA Category 2 "Do Not Compound" list on April 15, 2026, following withdrawal of the original nomination. Removal from Category 2 does not authorize compounding — formal FDA rulemaking is still required. Update (August 2026): The FDA has confirmed a second PCAC hearing will convene on or before February 28, 2027 to evaluate Melanotan II, LL-37, injectable GHK-Cu, Dihexa, and PEG-MGF for the 503A Bulk Drug Substances List. Melanotan II remains off the 503A Bulks List pending that review. TGA Notice (June 2026): Australia's Therapeutic Goods Administration formally designated unapproved peptide products — including Melanotan II — as a 2026 compliance enforcement priority. These compounds are not registered therapeutic goods in Australia; they may not be lawfully imported, supplied, or advertised for human therapeutic use. Sources: FDA.gov; tga.gov.au (June 10, 2026); peptideknow.com (PCAC second tranche, July 2026). TGA Active Enforcement (August 4, 2026): TGA officers and NSW Police executed search warrants at two residential properties in New South Wales on August 4, 2026, seizing more than $120,000 worth of illicit peptide and anabolic steroid products. The properties were linked to a social media influencer who had previously been warned by the TGA for importing, relabelling, advertising, and supplying unapproved peptide products — a pattern of supply-side enforcement now escalating beyond warnings to physical raids. Source: TGA media release, tga.gov.au (August 17, 2026). TGA Dosing Safety Alert (August 17, 2026): The TGA published a formal safety alert — "Melanotan II tanning peptide products found to be inconsistently dosed" — after laboratory testing of seized products revealed extreme dosing variance. Testing of five bottles of a nasal spray labelled "Pure Tans Triple Strength 30 MG" showed the estimated amount of Melanotan II varied from 22mg to 54mg per bottle — representing a more than 2× range within products carrying the same label. The TGA also announced it had issued 27 infringement notices totalling AUD$101,412 to a NSW-based individual for the alleged unlawful supply of Melanotan II to Australian consumers. Infringement notices were paid in May 2026. The alert underscores that unregulated Melanotan II products are prescription-only medicines in Australia, carry serious health risks, and may not contain the amount stated on the label. Source: TGA safety alert (tga.gov.au, August 17, 2026); 7News (August 17, 2026); TGA media release on individual issued 27 infringement notices (tga.gov.au).

Regulatory Notice (August 2026): LL-37 Complex was removed from the FDA Category 2 "Do Not Compound" list on April 15, 2026, following withdrawal of the original nomination. Removal from Category 2 does not authorize compounding — formal FDA rulemaking is still required. Update (August 2026): The FDA has confirmed a second PCAC hearing will convene on or before February 28, 2027 to evaluate LL-37, injectable GHK-Cu, Dihexa, Melanotan II, and PEG-MGF for the 503A Bulk Drug Substances List. LL-37 remains off the 503A Bulks List pending that review. Sources: FDA.gov; peptideknow.com (PCAC second tranche, July 2026); meto.co (FDA Peptide Decision 2026, July 24, 2026).

Regulatory Notice (August 2026): LL-37 was removed from the FDA Category 2 "Do Not Compound" list on April 15, 2026, following withdrawal of the original nomination. Removal from Category 2 does not authorize compounding — formal FDA rulemaking is still required. Update (August 2026): The FDA has confirmed a second PCAC hearing will convene on or before February 28, 2027 to evaluate LL-37, injectable GHK-Cu, Dihexa, Melanotan II, and PEG-MGF for the 503A Bulk Drug Substances List. LL-37 remains off the 503A Bulks List pending that review. Sources: FDA.gov; peptideknow.com (PCAC second tranche, July 2026); meto.co (FDA Peptide Decision 2026, July 24, 2026).

Regulatory Notice (July 2026): GHK-Cu has a split FDA 503A status as of May 2026. Non-injectable GHK-Cu (topical, cream, serum formulations) was restored to 503A Category 1 on May 14, 2026, following withdrawal of the injectable-route nomination on May 5, 2026 — non-injectable use remains under standard Category 1 evaluation. Injectable GHK-Cu remains excluded from the 503A bulks list and is not authorized for compounding. GHK-Cu is NOT on the July 23–24, 2026 PCAC agenda; a full PCAC review is expected by early 2027. Note: removal from Category 2 does not constitute FDA approval or authorization for compounding — formal FDA rulemaking is still required for any Category 1 listing. ANSM Safety Alert — France (July 2, 2026): France's national medicines regulatory agency (ANSM) published a formal public safety alert titled 'Peptides vendus en ligne: ne les utilisez pas, ils peuvent être dangereux' (Peptides sold online: do not use them, they can be dangerous). The alert cites pharmacovigilance reports of serious adverse events — including hospitalizations — in individuals aged 15 to 35 following use of injectable peptides purchased online, including retatrutide, BPC-157, TB-500, GHK-Cu, NAD+, and growth hormone products. The ANSM states that these compounds are not authorized or evaluated for human use in France, warns that products sold informally (online, social media, peer networks) are not subject to quality or safety controls, and flags a potential cancer-progression risk from unregulated cell-growth stimulants. The ANSM strongly advises the French public not to acquire or use these compounds. This alert does not affect the research-use legal status of these compounds globally but confirms that EU-member regulators are actively monitoring and taking enforcement action on the supply side. Source: ANSM (ansm.sante.fr, July 2, 2026); VIDAL.fr (July 2, 2026); AFP/actualites-sante.com (July 3, 2026).

Regulatory Notice (July 2026): GHK-Cu has a split FDA 503A status as of May 2026. Non-injectable GHK-Cu (topical, cream, serum formulations) was restored to 503A Category 1 on May 14, 2026, following withdrawal of the injectable-route nomination on May 5, 2026 — non-injectable use remains under standard Category 1 evaluation. Injectable GHK-Cu remains excluded from the 503A bulks list and is not authorized for compounding. GHK-Cu is NOT on the July 23–24, 2026 PCAC agenda; a full PCAC review is expected by early 2027. Note: removal from Category 2 does not constitute FDA approval or authorization for compounding — formal FDA rulemaking is still required for any Category 1 listing. ANSM Safety Alert — France (July 2, 2026): France's national medicines regulatory agency (ANSM) published a formal public safety alert titled 'Peptides vendus en ligne: ne les utilisez pas, ils peuvent être dangereux' (Peptides sold online: do not use them, they can be dangerous). The alert cites pharmacovigilance reports of serious adverse events — including hospitalizations — in individuals aged 15 to 35 following use of injectable peptides purchased online, including retatrutide, BPC-157, TB-500, GHK-Cu, NAD+, and growth hormone products. The ANSM states that these compounds are not authorized or evaluated for human use in France, warns that products sold informally (online, social media, peer networks) are not subject to quality or safety controls, and flags a potential cancer-progression risk from unregulated cell-growth stimulants. The ANSM strongly advises the French public not to acquire or use these compounds. This alert does not affect the research-use legal status of these compounds globally but confirms that EU-member regulators are actively monitoring and taking enforcement action on the supply side. Source: ANSM (ansm.sante.fr, July 2, 2026); VIDAL.fr (July 2, 2026); AFP/actualites-sante.com (July 3, 2026).

Regulatory Notice (July 24, 2026 — PCAC VOTE OUTCOME): On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted in favor of recommending KPV for inclusion on the 503A Bulk Drug Substances List (8–6 vote, 1 abstention) — overriding the FDA staff's own recommendation against it. This is an advisory recommendation only; formal FDA rulemaking (typically 12–24 months) is required before compounding pharmacies can legally prepare KPV. Sources: RAPS (July 24, 2026); NPR (July 23, 2026); FDA.gov PCAC July 23-24 meeting.

Regulatory Notice:TGA Notice (June 2026): Australia's Therapeutic Goods Administration formally designated unapproved peptide products — including BPC-157 and TB-500 — as 2026 compliance enforcement priorities (TGA media release, June 10, 2026). These compounds are not registered therapeutic goods in Australia; they may not be lawfully imported, supplied, or advertised for human therapeutic use. Source: tga.gov.au/news/media-releases/tga-strengthens-compliance-focus-unapproved-peptide-products. Update (July 23–24, 2026): PCAC voted to recommend this compound for inclusion on the 503A Bulk Drug Substances List, overriding the FDA staff recommendation. A favorable PCAC recommendation is not FDA approval and does not immediately authorize compounding — formal notice-and-comment rulemaking (typically 12–24 months) must conclude before 503A compounding pharmacies may legally prepare this compound. The FDA is not bound by the advisory vote. Source: FDA.gov/advisory-committees (July 23–24, 2026 PCAC meeting); NPR (July 23, 2026); NYT (July 24, 2026). TGA Escalation (July 20, 2026): The TGA wrote directly to social media and e-commerce platforms to halt unlawful advertising, and issued formal notices to peptide promoters and suppliers stating: 'If you are unlawfully importing, manufacturing, advertising or supplying unapproved peptide products, expect the TGA to take action.' This marks a shift from consumer education to active enforcement against supply-side operators. Source: TGA media release, July 20, 2026 (tga.gov.au). TGA Active Enforcement (August 4, 2026): TGA officers and NSW Police executed search warrants at two residential properties in New South Wales on August 4, 2026, seizing more than $120,000 worth of illicit peptide and anabolic steroid products. The properties were linked to a social media influencer who had previously been warned by the TGA for importing, relabelling, advertising, and supplying unapproved peptide products — a pattern of supply-side enforcement now escalating beyond warnings to physical raids. Source: TGA media release, tga.gov.au (August 17, 2026). ANSM Safety Alert — France (July 2, 2026): France's national medicines regulatory agency (ANSM) published a formal public safety alert titled 'Peptides vendus en ligne: ne les utilisez pas, ils peuvent être dangereux' (Peptides sold online: do not use them, they can be dangerous). The alert cites pharmacovigilance reports of serious adverse events — including hospitalizations — in individuals aged 15 to 35 following use of injectable peptides purchased online, including retatrutide, BPC-157, TB-500, GHK-Cu, NAD+, and growth hormone products. The ANSM states that these compounds are not authorized or evaluated for human use in France, warns that products sold informally (online, social media, peer networks) are not subject to quality or safety controls, and flags a potential cancer-progression risk from unregulated cell-growth stimulants. The ANSM strongly advises the French public not to acquire or use these compounds. This alert does not affect the research-use legal status of these compounds globally but confirms that EU-member regulators are actively monitoring and taking enforcement action on the supply side. Source: ANSM (ansm.sante.fr, July 2, 2026); VIDAL.fr (July 2, 2026); AFP/actualites-sante.com (July 3, 2026).

Regulatory Notice (July 2026): Retatrutide is not FDA approved. The TRIUMPH-1 Phase 3 trial (2,339 participants, 80 weeks) reported a mean body weight reduction of 28.3%, with reductions up to 30.3% in higher-BMI cohorts — announced May 21, 2026. Additional TRIUMPH-1 secondary endpoints announced June 6, 2026 at ADA Scientific Sessions: 60.6% reduction in Apnea-Hypopnea Index in patients with obstructive sleep apnea (source: Eli Lilly investor release, investor.lilly.com). Update (July 23, 2026): Eli Lilly announced positive results from TRIUMPH-2 (adults with obesity and type 2 diabetes; 22.6% mean weight loss at 80 weeks) and TRIUMPH-3 (adults with severe obesity and cardiovascular disease; up to 22.6% mean weight loss at 80 weeks), completing the Phase 3 programme. Lilly confirmed it plans to submit a Biologics License Application (BLA) to the FDA in Q1 2027. FDA approval is not anticipated before late 2027 at the earliest. Sources: Eli Lilly press release July 23, 2026 (investor.lilly.com); PharmExec July 25, 2026; Pharmaphorum July 22, 2026. Retatrutide cannot be legally compounded under 503A or 503B. Research compound only. Enforcement Action (August 12, 2026): Eli Lilly filed six civil lawsuits against U.S. entities selling black-market, unapproved versions of retatrutide — an investigational compound that has not received FDA approval. Lilly simultaneously referred hundreds of additional bad actors to regulators and law enforcement worldwide, and called on online platforms and payment companies to shut off access to illicit sellers. The actions underscore that retatrutide cannot be legally compounded, sold, or distributed outside of the authorised clinical trial framework. Source: Eli Lilly investor press release (investor.lilly.com, August 12, 2026); Reuters (August 12, 2026); Healio (August 14, 2026). ANSM Safety Alert — France (July 2, 2026): France's national medicines regulatory agency (ANSM) published a formal public safety alert titled 'Peptides vendus en ligne: ne les utilisez pas, ils peuvent être dangereux' (Peptides sold online: do not use them, they can be dangerous). The alert cites pharmacovigilance reports of serious adverse events — including hospitalizations — in individuals aged 15 to 35 following use of injectable peptides purchased online, including retatrutide, BPC-157, TB-500, GHK-Cu, NAD+, and growth hormone products. The ANSM states that these compounds are not authorized or evaluated for human use in France, warns that products sold informally (online, social media, peer networks) are not subject to quality or safety controls, and flags a potential cancer-progression risk from unregulated cell-growth stimulants. The ANSM strongly advises the French public not to acquire or use these compounds. This alert does not affect the research-use legal status of these compounds globally but confirms that EU-member regulators are actively monitoring and taking enforcement action on the supply side. Source: ANSM (ansm.sante.fr, July 2, 2026); VIDAL.fr (July 2, 2026); AFP/actualites-sante.com (July 3, 2026). Biologic Classification Dispute — Seventh Circuit (August 2026): A federal court vacated the FDA's classification of retatrutide as a "drug" in September 2025 and remanded the question to the agency. Eli Lilly appealed to the Seventh Circuit Court of Appeals in February 2026, asking that retatrutide be classified as a biological product outright. Oral arguments before the Seventh Circuit are scheduled for September 24, 2026. The distinction is legally significant: a biologic classification would entitle Lilly to 12 years of exclusivity under the Biologics Price Competition and Innovation Act — longer than the standard 5-year New Chemical Entity exclusivity available for small-molecule drugs — and would permanently foreclose any compounding access, as biologics cannot be placed on the 503A or 503B Bulks Lists. The FDA's remand analysis (now required regardless of the court outcome) will also establish a binding standard for what makes a peptide "analogous to a protein," which may affect the classification of other large peptide therapeutics in development. No court ruling has been issued as of August 21, 2026. Sources: thepeptidetoolkit.com (May 21, 2026); compoundprotocol.com (August 11, 2026); BioSpace (August 5, 2026). TGA Safety Alert — Australia (September 14, 2026): Australia's Therapeutic Goods Administration issued a public safety warning after a patient suffered a torn oesophagus requiring hospitalisation following use of a product sold as retatrutide. Laboratory analysis confirmed the vial contained no retatrutide — instead it held a high and undeclared dose of semaglutide, consistent with deliberate counterfeiting. The TGA warns that illicit peptide products sold online — including those labelled as retatrutide — may be mislabelled, contaminated, or contain entirely different active substances. Consumers who experienced severe vomiting or GI symptoms after using such products are advised to seek immediate medical attention. Retatrutide is not approved by the TGA or any regulatory authority. The incident underscores the serious injury risk from counterfeit and unapproved injectable peptides obtained outside authorised clinical trial channels. Sources: ABC News Australia (abc.net.au, September 14, 2026); The Guardian Australia (theguardian.com, September 14, 2026); pharmex.co (September 14, 2026).

Regulatory Notice (May 2026): The FDA proposed on April 30, 2026 to remove Semaglutide and Tirzepatide from the 503B compounding bulks list. The national shortage designation has been resolved. Compounded versions of these compounds may face legal restrictions. Verify current FDA compounding status in your region before sourcing.

Regulatory Notice (July 2026): CagriSema (cagrilintide + semaglutide) NDA filed with the FDA on December 18, 2025 (Novo Nordisk). FDA decision expected Q4 2026 (PDUFA target date: December 31, 2026 — confirmed per FDA acceptance and Novo Nordisk investor disclosure as of September 2, 2026; source: pdufa.bio/pdufa/NVO-cagrisema, September 2, 2026). REDEFINE 1 Phase 3: 22.7% weight loss at 68 weeks. REDEFINE 4 (head-to-head vs. tirzepatide): 23.0% vs. 25.5% — did not achieve non-inferiority. Cagrilintide alone and CagriSema blend are not FDA approved. Research compounds pending approval decision. FDA Enforcement Action — Misleading Compounded GLP-1 Marketing (March 3, 2026): On March 3, 2026, the FDA issued 30 warning letters to telehealth companies for making false or misleading marketing claims about compounded GLP-1 receptor agonist products, including claims implying equivalence to FDA-approved brand-name medications (Ozempic, Wegovy, Mounjaro, Zepbound) and branding that obscured the identity of the actual compounder. This is a distinct enforcement action — separate from the 503B exclusion proposal (April 30, 2026) — and targets promotional violations rather than compounding authorization. Researchers and clinicians following this space should be aware that FDA is actively enforcing truthful labeling rules in the compounded GLP-1 market. Source: FDA press announcement (fda.gov, March 3, 2026); Reuters (March 3, 2026). Fifth Circuit Court of Appeals — GLP-1 Compounding Ruling (August 27, 2026): On August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit affirmed two lower-court judgments upholding the FDA's removal of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) from the national drug shortage list. Because federal law (21 U.S.C. § 353a/353b) only permits compounding copies of an approved drug while it remains in shortage, this ruling removes the shortage-based legal basis for bulk compounding of these agents. 503A patient-specific compounding for individual patients with documented medical needs remains a separate, narrower pathway. 503B outsourcing facility bulk production of essentially-equivalent copies is no longer supported by a shortage justification. The ruling does not affect the separate FDA rulemaking (503B exclusion proposal, April 30, 2026) which is still under agency review. Sources: teleranked.com (August 27, 2026); peptidesbeat.com (August 27, 2026); courthousenews.com. FDA Import Alert 66-80 — GLP-1 API Detention (August 21, 2026): On August 21, 2026, the FDA published a major revision to Import Alert 66-80, authorising Detention Without Physical Examination (DWPE) of foreign-sourced GLP-1 receptor agonist bulk drug substances — including semaglutide, tirzepatide, liraglutide, exenatide, dulaglutide, and related peptide APIs — at U.S. ports of entry. The alert accompanies the FDA's "green list" program: manufacturers that have passed FDA inspection and cGMP review can apply to be exempted from automatic detention. Facilities that have not responded to FDA inspection requests or have been found non-compliant remain subject to DWPE. Practically, this means bulk GLP-1 API imported from foreign sources without green-list status can be detained and refused entry without individual inspection. This is a supply-chain enforcement tool targeting the import of raw GLP-1 peptide APIs used in compounding; it does not change whether compounding is otherwise permitted. The alert operates in parallel with the ongoing 503B exclusion rulemaking (comment period closed July 30, 2026, final rule pending) and the Fifth Circuit ruling (August 27, 2026) upholding removal of these agents from shortage status. Source: FDA Import Alert 66-80, accessdata.fda.gov (August 21, 2026); FDA press announcement (fda.gov); Frier Levitt (frierlevitt.com); PeptideKnow.com.

Regulatory Notice (August 2026): Dihexa was not reviewed at the July 23–24, 2026 PCAC hearing. The FDA has confirmed a second PCAC hearing will convene on or before February 28, 2027 to evaluate Dihexa, LL-37, injectable GHK-Cu, Melanotan II, and PEG-MGF for the 503A Bulk Drug Substances List. Dihexa remains off the 503A Bulks List with no authorized compounding pathway as of August 2026. Note: the foundational 2014 mechanism paper was formally retracted in April 2025 due to falsified data. Sources: FDA.gov; peptideknow.com (PCAC second tranche, July 2026); meto.co (FDA Peptide Decision 2026, July 24, 2026).

Regulatory Notice:TGA Notice (June 2026): Australia's Therapeutic Goods Administration formally designated unapproved peptide products — including BPC-157 and TB-500 — as 2026 compliance enforcement priorities (TGA media release, June 10, 2026). These compounds are not registered therapeutic goods in Australia; they may not be lawfully imported, supplied, or advertised for human therapeutic use. Source: tga.gov.au/news/media-releases/tga-strengthens-compliance-focus-unapproved-peptide-products. Update (July 23–24, 2026): PCAC voted to recommend this compound for inclusion on the 503A Bulk Drug Substances List, overriding the FDA staff recommendation. A favorable PCAC recommendation is not FDA approval and does not immediately authorize compounding — formal notice-and-comment rulemaking (typically 12–24 months) must conclude before 503A compounding pharmacies may legally prepare this compound. The FDA is not bound by the advisory vote. Source: FDA.gov/advisory-committees (July 23–24, 2026 PCAC meeting); NPR (July 23, 2026); NYT (July 24, 2026). TGA Escalation (July 20, 2026): The TGA wrote directly to social media and e-commerce platforms to halt unlawful advertising, and issued formal notices to peptide promoters and suppliers stating: 'If you are unlawfully importing, manufacturing, advertising or supplying unapproved peptide products, expect the TGA to take action.' This marks a shift from consumer education to active enforcement against supply-side operators. Source: TGA media release, July 20, 2026 (tga.gov.au). TGA Active Enforcement (August 4, 2026): TGA officers and NSW Police executed search warrants at two residential properties in New South Wales on August 4, 2026, seizing more than $120,000 worth of illicit peptide and anabolic steroid products. The properties were linked to a social media influencer who had previously been warned by the TGA for importing, relabelling, advertising, and supplying unapproved peptide products — a pattern of supply-side enforcement now escalating beyond warnings to physical raids. Source: TGA media release, tga.gov.au (August 17, 2026). ANSM Safety Alert — France (July 2, 2026): France's national medicines regulatory agency (ANSM) published a formal public safety alert titled 'Peptides vendus en ligne: ne les utilisez pas, ils peuvent être dangereux' (Peptides sold online: do not use them, they can be dangerous). The alert cites pharmacovigilance reports of serious adverse events — including hospitalizations — in individuals aged 15 to 35 following use of injectable peptides purchased online, including retatrutide, BPC-157, TB-500, GHK-Cu, NAD+, and growth hormone products. The ANSM states that these compounds are not authorized or evaluated for human use in France, warns that products sold informally (online, social media, peer networks) are not subject to quality or safety controls, and flags a potential cancer-progression risk from unregulated cell-growth stimulants. The ANSM strongly advises the French public not to acquire or use these compounds. This alert does not affect the research-use legal status of these compounds globally but confirms that EU-member regulators are actively monitoring and taking enforcement action on the supply side. Source: ANSM (ansm.sante.fr, July 2, 2026); VIDAL.fr (July 2, 2026); AFP/actualites-sante.com (July 3, 2026).

Regulatory Notice:TGA Notice (June 2026): Australia's Therapeutic Goods Administration formally designated unapproved peptide products — including BPC-157 and TB-500 — as 2026 compliance enforcement priorities (TGA media release, June 10, 2026). These compounds are not registered therapeutic goods in Australia; they may not be lawfully imported, supplied, or advertised for human therapeutic use. Source: tga.gov.au/news/media-releases/tga-strengthens-compliance-focus-unapproved-peptide-products. Update (July 23–24, 2026): PCAC voted to recommend this compound for inclusion on the 503A Bulk Drug Substances List, overriding the FDA staff recommendation. A favorable PCAC recommendation is not FDA approval and does not immediately authorize compounding — formal notice-and-comment rulemaking (typically 12–24 months) must conclude before 503A compounding pharmacies may legally prepare this compound. The FDA is not bound by the advisory vote. Source: FDA.gov/advisory-committees (July 23–24, 2026 PCAC meeting); NPR (July 23, 2026); NYT (July 24, 2026). TGA Escalation (July 20, 2026): The TGA wrote directly to social media and e-commerce platforms to halt unlawful advertising, and issued formal notices to peptide promoters and suppliers stating: 'If you are unlawfully importing, manufacturing, advertising or supplying unapproved peptide products, expect the TGA to take action.' This marks a shift from consumer education to active enforcement against supply-side operators. Source: TGA media release, July 20, 2026 (tga.gov.au). TGA Active Enforcement (August 4, 2026): TGA officers and NSW Police executed search warrants at two residential properties in New South Wales on August 4, 2026, seizing more than $120,000 worth of illicit peptide and anabolic steroid products. The properties were linked to a social media influencer who had previously been warned by the TGA for importing, relabelling, advertising, and supplying unapproved peptide products — a pattern of supply-side enforcement now escalating beyond warnings to physical raids. Source: TGA media release, tga.gov.au (August 17, 2026). ANSM Safety Alert — France (July 2, 2026): France's national medicines regulatory agency (ANSM) published a formal public safety alert titled 'Peptides vendus en ligne: ne les utilisez pas, ils peuvent être dangereux' (Peptides sold online: do not use them, they can be dangerous). The alert cites pharmacovigilance reports of serious adverse events — including hospitalizations — in individuals aged 15 to 35 following use of injectable peptides purchased online, including retatrutide, BPC-157, TB-500, GHK-Cu, NAD+, and growth hormone products. The ANSM states that these compounds are not authorized or evaluated for human use in France, warns that products sold informally (online, social media, peer networks) are not subject to quality or safety controls, and flags a potential cancer-progression risk from unregulated cell-growth stimulants. The ANSM strongly advises the French public not to acquire or use these compounds. This alert does not affect the research-use legal status of these compounds globally but confirms that EU-member regulators are actively monitoring and taking enforcement action on the supply side. Source: ANSM (ansm.sante.fr, July 2, 2026); VIDAL.fr (July 2, 2026); AFP/actualites-sante.com (July 3, 2026).

Regulatory Notice (May 2026): The FDA proposed on April 30, 2026 to remove Semaglutide and Tirzepatide from the 503B compounding bulks list. The national shortage designation has been resolved. Compounded versions of these compounds may face legal restrictions. Verify current FDA compounding status in your region before sourcing.

Regulatory Notice (June 2026): Oral semaglutide (Wegovy® Pill) received FDA approval for weight management in January 2026. It is an approved prescription pharmaceutical — not a research peptide. Only FDA-approved branded Wegovy® Pill is legal for human use. Compounded oral semaglutide is not authorized under any current FDA pathway. FDA Enforcement Action — Misleading Compounded GLP-1 Marketing (March 3, 2026): On March 3, 2026, the FDA issued 30 warning letters to telehealth companies for making false or misleading marketing claims about compounded GLP-1 receptor agonist products, including claims implying equivalence to FDA-approved brand-name medications (Ozempic, Wegovy, Mounjaro, Zepbound) and branding that obscured the identity of the actual compounder. This is a distinct enforcement action — separate from the 503B exclusion proposal (April 30, 2026) — and targets promotional violations rather than compounding authorization. Researchers and clinicians following this space should be aware that FDA is actively enforcing truthful labeling rules in the compounded GLP-1 market. Source: FDA press announcement (fda.gov, March 3, 2026); Reuters (March 3, 2026). Fifth Circuit Court of Appeals — GLP-1 Compounding Ruling (August 27, 2026): On August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit affirmed two lower-court judgments upholding the FDA's removal of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) from the national drug shortage list. Because federal law (21 U.S.C. § 353a/353b) only permits compounding copies of an approved drug while it remains in shortage, this ruling removes the shortage-based legal basis for bulk compounding of these agents. 503A patient-specific compounding for individual patients with documented medical needs remains a separate, narrower pathway. 503B outsourcing facility bulk production of essentially-equivalent copies is no longer supported by a shortage justification. The ruling does not affect the separate FDA rulemaking (503B exclusion proposal, April 30, 2026) which is still under agency review. Sources: teleranked.com (August 27, 2026); peptidesbeat.com (August 27, 2026); courthousenews.com. FDA Import Alert 66-80 — GLP-1 API Detention (August 21, 2026): On August 21, 2026, the FDA published a major revision to Import Alert 66-80, authorising Detention Without Physical Examination (DWPE) of foreign-sourced GLP-1 receptor agonist bulk drug substances — including semaglutide, tirzepatide, liraglutide, exenatide, dulaglutide, and related peptide APIs — at U.S. ports of entry. The alert accompanies the FDA's "green list" program: manufacturers that have passed FDA inspection and cGMP review can apply to be exempted from automatic detention. Facilities that have not responded to FDA inspection requests or have been found non-compliant remain subject to DWPE. Practically, this means bulk GLP-1 API imported from foreign sources without green-list status can be detained and refused entry without individual inspection. This is a supply-chain enforcement tool targeting the import of raw GLP-1 peptide APIs used in compounding; it does not change whether compounding is otherwise permitted. The alert operates in parallel with the ongoing 503B exclusion rulemaking (comment period closed July 30, 2026, final rule pending) and the Fifth Circuit ruling (August 27, 2026) upholding removal of these agents from shortage status. Source: FDA Import Alert 66-80, accessdata.fda.gov (August 21, 2026); FDA press announcement (fda.gov); Frier Levitt (frierlevitt.com); PeptideKnow.com.

Regulatory Notice (June 2026): SLU-PP-332 is an early-stage research compound with no human clinical trials, no FDA approval, and no approved therapeutic use. It is not available from licensed compounding pharmacies. Grey-market sources carry unknown purity risks. Research use only.